{"f068fb4e76c0b392c86870b455c3336c7fb3eb1f": [["Death_cases_of_India= [12, 20, 20, 24, 27, 32, 35, 58, 72, 72, 86, 99, 136, 150, 178, 226, 246, 288, 331, 358, 393] Recovered_cases_of_India= [43,45,73,84,95,102,123,148,191,192,229,229,375,421,506,620,774,969,108 0,1181,1359] R=[x + y for x, y in zip(Death_cases_of_India, Recovered_cases_of_India)] Total_confirmed_cases_of_India=[12322,13430,14352,15722,17615,18539,20080,21370,23077,24530,2 6283,27890,29451,31324,33062,34863,37257,39699,42505] Death_cases_of_India= [405,448,486,521,559,592,645,681,721,780,825,881,939,1008,1079,1154,1223,1 323,1391] Recovered_cases_of_India= [1432,1768,2041,2463,2854,3273,3975,4370,5012,5498,5939,6523,7137,77 47,8437,9068,10007,10819,11775] R=[x + y for x, y in zip(Death_cases_of_India, Recovered_cases_of_India)] #DATASET FROM JHU-CSSE: https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series #FOR TOTAL CONFIRMED CASES: https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_global.csv #FOR DEATHS: https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_deaths_global.csv #FOR RECOVERED: https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_recovered_global.csv Total_confirmed_cases_of_India=[46437,49400,52987,56351,59695,62808,67161,70768,74292,78055,8 1997,85784,90648,95698] Death_cases_of_India= [1566, 1693, 1785, 1889, 1985, 2101, 2212, 2294, 2415, 2551, 2649, 2753, 2871, 3025] Recovered_cases_of_India= [12847, 14142, 15331, 16776, 17887, 19301, 20969, 22549, 24420, 26400, 27969, 30258, 34224, 36795] R=[x + y for x, y in zip(Death_cases_of_India, Recovered_cases_of_India)] plt.title('t_max= %g, I_max= %2.3g%%, S_inf: %2.4g%%' % (tmax, Imax/N100))", [["Total_confirmed_cases_of_India=[46437,49400,52987,56351,59695,62808,67161,70768,74292,78055,8 1997,85784,90648,95698", "CHEMICAL", 1388, 1504], ["[12847, 14142, 15331, 16776, 17887, 19301, 20969, 22549, 24420, 26400, 27969, 30258, 34224, 36795", "CHEMICAL", 1639, 1736], ["Death_cases_of_India", "TEST", 0, 20], ["Recovered_cases_of_India", "TEST", 116, 140], ["https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_global.csv", "PROBLEM", 909, 1059], ["https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_deaths_global.csv", "PROBLEM", 1073, 1220], ["https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_recovered_global.csv", "PROBLEM", 1237, 1387], ["t_max", "TEST", 1823, 1828], ["I_max", "TEST", 1834, 1839], ["S_inf", "TEST", 1850, 1855], ["tmax", "TEST", 1869, 1873]]]], "798b4341bd871aaaad19ad0beca4cb5f3c639bef": [["The outbreak of the novel coronavirus disease, COVID-19, caused by coronavirus 2019-nCoV officially designated as severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2), represents a pandemic threat to global public health [1, 2] .", [["coronavirus disease", "DISEASE", 26, 45], ["COVID-19", "CHEMICAL", 47, 55], ["coronavirus 2019-nCoV", "CHEMICAL", 67, 88], ["acute respiratory syndrome", "DISEASE", 121, 147], ["coronavirus", "ORGANISM", 26, 37], ["COVID-19", "ORGANISM", 47, 55], ["coronavirus 2019-nCoV", "ORGANISM", 67, 88], ["severe acute respiratory syndrome related coronavirus 2", "ORGANISM", 114, 169], ["SARS-CoV-2", "ORGANISM", 171, 181], ["coronavirus", "SPECIES", 26, 37], ["coronavirus", "SPECIES", 67, 78], ["COVID-19", "SPECIES", 47, 55], ["coronavirus 2019-nCoV", "SPECIES", 67, 88], ["severe acute respiratory syndrome related coronavirus", "SPECIES", 114, 167], ["SARS-CoV-2", "SPECIES", 171, 181], ["the novel coronavirus disease", "PROBLEM", 16, 45], ["COVID", "TEST", 47, 52], ["coronavirus", "TEST", 67, 78], ["severe acute respiratory syndrome", "PROBLEM", 114, 147], ["coronavirus", "PROBLEM", 156, 167], ["SARS-CoV", "TEST", 171, 179], ["coronavirus disease", "OBSERVATION", 26, 45], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["respiratory syndrome", "OBSERVATION", 127, 147]]]], "cb4329443ac239206d141512286241e8a7570ea2": [["Talking to children about illness and death of a loved one during the COVID-19 pandemic", [["illness", "DISEASE", 26, 33], ["death", "DISEASE", 38, 43], ["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19]]]], "8e354d1cc21a56062fcc5fe4571a791e9bc45d75": [["COVID-19 is a pandemic illness forcing clinicians and clinician scientists to respond to an unforeseen 20% rate of hospital admissions due to respiratory distress and a sepsis-like hyperinflammatory cytokine release syndrome that develops in a subgroup of SARS-CoV2-infected patients.", [["respiratory", "ANATOMY", 142, 153], ["pandemic illness", "DISEASE", 14, 30], ["respiratory distress", "DISEASE", 142, 162], ["sepsis", "DISEASE", 169, 175], ["SARS-CoV2-infected", "DISEASE", 256, 274], ["SARS-CoV2", "ORGANISM", 256, 265], ["patients", "ORGANISM", 275, 283], ["cytokine", "PROTEIN", 199, 207], ["patients", "SPECIES", 275, 283], ["respiratory distress", "PROBLEM", 142, 162], ["a sepsis", "PROBLEM", 167, 175], ["hyperinflammatory cytokine release syndrome", "PROBLEM", 181, 224], ["respiratory", "ANATOMY", 142, 153], ["distress", "OBSERVATION", 154, 162], ["sepsis", "OBSERVATION", 169, 175], ["hyperinflammatory cytokine release syndrome", "OBSERVATION", 181, 224], ["infected", "OBSERVATION", 266, 274]]], ["Initial results of the WUHAN COVID-19 cohort suggested a major impact of hyperinflammation characterized by a specific cytokine profile including IL-1\u03b2, IL-6, and TNF-\u03b1 on patient outcome.", [["hyperinflammation", "DISEASE", 73, 90], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 146, 151], ["IL-6", "GENE_OR_GENE_PRODUCT", 153, 157], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 163, 168], ["patient", "ORGANISM", 172, 179], ["cytokine", "PROTEIN", 119, 127], ["IL-6", "PROTEIN", 153, 157], ["TNF", "PROTEIN", 163, 166], ["patient", "SPECIES", 172, 179], ["the WUHAN COVID", "TEST", 19, 34], ["hyperinflammation", "PROBLEM", 73, 90], ["IL", "TEST", 146, 148], ["TNF", "TEST", 163, 166], ["hyperinflammation", "OBSERVATION", 73, 90]]], ["Lessons learned from the novel coronavirus outbreak combined with knowledge that accumulated after the first SARS epidemic have revealed a biphasic pulmonary immune response.", [["pulmonary", "ANATOMY", 148, 157], ["coronavirus", "DISEASE", 31, 42], ["SARS", "DISEASE", 109, 113], ["coronavirus", "ORGANISM", 31, 42], ["pulmonary", "ORGAN", 148, 157], ["the novel coronavirus outbreak", "PROBLEM", 21, 51], ["the first SARS epidemic", "PROBLEM", 99, 122], ["a biphasic pulmonary immune response", "PROBLEM", 137, 173], ["coronavirus", "OBSERVATION_MODIFIER", 31, 42], ["biphasic", "OBSERVATION_MODIFIER", 139, 147], ["pulmonary", "ANATOMY", 148, 157], ["immune response", "OBSERVATION", 158, 173]]], ["The majority of individuals recover after an initial virusclearing IFN-I response.", [["individuals", "ORGANISM", 16, 27], ["IFN-I", "GENE_OR_GENE_PRODUCT", 67, 72], ["IFN", "PROTEIN", 67, 70]]], ["Yet, with \"false fine-tuning\" regulated by host and environmental factors, the immuneresponse can accelerate to a second cytokine wave leading to recruitment of lymphocytes and macrophages to the lung which in turn governs the development of acute respiratory distress syndrome (ARDS) and progressive hyperferritinemic hyperinflammation.", [["lymphocytes", "ANATOMY", 161, 172], ["macrophages", "ANATOMY", 177, 188], ["lung", "ANATOMY", 196, 200], ["respiratory", "ANATOMY", 248, 259], ["acute respiratory distress syndrome", "DISEASE", 242, 277], ["ARDS", "DISEASE", 279, 283], ["hyperinflammation", "DISEASE", 319, 336], ["lymphocytes", "CELL", 161, 172], ["macrophages", "CELL", 177, 188], ["lung", "ORGAN", 196, 200], ["cytokine", "PROTEIN", 121, 129], ["lymphocytes", "CELL_TYPE", 161, 172], ["macrophages", "CELL_TYPE", 177, 188], ["a second cytokine wave", "PROBLEM", 112, 134], ["recruitment of lymphocytes", "PROBLEM", 146, 172], ["macrophages to the lung", "PROBLEM", 177, 200], ["acute respiratory distress syndrome", "PROBLEM", 242, 277], ["ARDS", "PROBLEM", 279, 283], ["progressive hyperferritinemic hyperinflammation", "PROBLEM", 289, 336], ["lymphocytes", "OBSERVATION", 161, 172], ["lung", "ANATOMY", 196, 200], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["respiratory distress syndrome", "OBSERVATION", 248, 277], ["ARDS", "OBSERVATION", 279, 283], ["progressive", "OBSERVATION_MODIFIER", 289, 300], ["hyperferritinemic hyperinflammation", "OBSERVATION", 301, 336]]], ["Rarely but dangerously, this culminates in macrophage activation syndrome (MAS) like sepsis with multiorgan failure.", [["macrophage", "ANATOMY", 43, 53], ["multiorgan", "ANATOMY", 97, 107], ["MAS", "DISEASE", 75, 78], ["sepsis", "DISEASE", 85, 91], ["multiorgan failure", "DISEASE", 97, 115], ["macrophage", "CELL", 43, 53], ["macrophage activation syndrome", "PROBLEM", 43, 73], ["sepsis", "PROBLEM", 85, 91], ["multiorgan failure", "PROBLEM", 97, 115], ["macrophage activation syndrome", "OBSERVATION", 43, 73], ["sepsis", "OBSERVATION", 85, 91], ["multiorgan failure", "OBSERVATION", 97, 115]]], ["The antiviral drug remdesivir (rem) applied at early stages and the corticosteroid dexamethasone (dex) in oxygen-dependent and severely affected patients by now seem the only disease-modifying agents with signals of efficacy in randomized controlled trials [1] .", [["remdesivir", "CHEMICAL", 19, 29], ["rem", "CHEMICAL", 31, 34], ["dexamethasone", "CHEMICAL", 83, 96], ["dex", "CHEMICAL", 98, 101], ["oxygen", "CHEMICAL", 106, 112], ["remdesivir", "CHEMICAL", 19, 29], ["dexamethasone", "CHEMICAL", 83, 96], ["dex", "CHEMICAL", 98, 101], ["oxygen", "CHEMICAL", 106, 112], ["remdesivir", "SIMPLE_CHEMICAL", 19, 29], ["rem", "SIMPLE_CHEMICAL", 31, 34], ["dexamethasone", "SIMPLE_CHEMICAL", 83, 96], ["dex", "SIMPLE_CHEMICAL", 98, 101], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["The antiviral drug remdesivir (rem)", "TREATMENT", 0, 35], ["the corticosteroid dexamethasone (dex", "TREATMENT", 64, 101], ["modifying agents", "TREATMENT", 183, 199]]], ["Rem seems to shorten recovery time, whereas dex impacts overall survival particularly in ARDS.", [["Rem", "CHEMICAL", 0, 3], ["ARDS", "DISEASE", 89, 93], ["ARDS", "PROBLEM", 89, 93], ["ARDS", "OBSERVATION", 89, 93]]], ["The British recovery trial demonstrating dex superiority over SOC supports the hypothesis that 6 mg of dex for 10 days helps to reverse pulmonary failure without putting patients on risk for secondary infections and delayed viral clearance.", [["pulmonary", "ANATOMY", 136, 145], ["dex", "CHEMICAL", 41, 44], ["dex", "CHEMICAL", 103, 106], ["pulmonary failure", "DISEASE", 136, 153], ["infections", "DISEASE", 201, 211], ["dex", "SIMPLE_CHEMICAL", 41, 44], ["dex", "SIMPLE_CHEMICAL", 103, 106], ["pulmonary", "ORGAN", 136, 145], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["dex superiority", "TREATMENT", 41, 56], ["dex", "TREATMENT", 103, 106], ["reverse pulmonary failure", "PROBLEM", 128, 153], ["secondary infections", "PROBLEM", 191, 211], ["delayed viral clearance", "PROBLEM", 216, 239], ["pulmonary", "ANATOMY", 136, 145], ["failure", "OBSERVATION", 146, 153], ["secondary", "OBSERVATION_MODIFIER", 191, 200], ["infections", "OBSERVATION", 201, 211], ["viral clearance", "OBSERVATION", 224, 239]]], ["Due to red flags put in place by the WHO and national medical societies regarding potentially detrimental steroid effects and the early data on cytokine release syndrome (CRS), a variety of compassionate use, targeted cytokine directed drugs have been reported in single case reports or case series, which were hypothesis-generating for prospective clinical trials.", [["steroid", "CHEMICAL", 106, 113], ["CRS", "DISEASE", 171, 174], ["steroid", "CHEMICAL", 106, 113], ["cytokine", "PROTEIN", 144, 152], ["cytokine", "PROTEIN", 218, 226], ["red flags", "PROBLEM", 7, 16], ["detrimental steroid effects", "TREATMENT", 94, 121], ["cytokine release syndrome", "PROBLEM", 144, 169], ["CRS", "PROBLEM", 171, 174], ["targeted cytokine directed drugs", "TREATMENT", 209, 241], ["prospective clinical trials", "TREATMENT", 337, 364], ["red flags", "OBSERVATION", 7, 16]]], ["As of August 1, 2020, the majority of reported cases involve IL-6R blocking tocilizumab, IL-1R blocking anakinra, and the multiple cytokines blocking JAK1/2 inhibitor baricitinib.", [["tocilizumab", "CHEMICAL", 76, 87], ["anakinra", "CHEMICAL", 104, 112], ["baricitinib", "CHEMICAL", 167, 178], ["baricitinib", "CHEMICAL", 167, 178], ["IL-6R", "SIMPLE_CHEMICAL", 61, 66], ["tocilizumab", "SIMPLE_CHEMICAL", 76, 87], ["IL-1R", "SIMPLE_CHEMICAL", 89, 94], ["anakinra", "SIMPLE_CHEMICAL", 104, 112], ["JAK1/2", "GENE_OR_GENE_PRODUCT", 150, 156], ["baricitinib", "SIMPLE_CHEMICAL", 167, 178], ["IL", "PROTEIN", 61, 63], ["cytokines", "PROTEIN", 131, 140], ["JAK1", "PROTEIN", 150, 154], ["IL", "TREATMENT", 61, 63], ["6R blocking tocilizumab", "TREATMENT", 64, 87], ["IL", "TREATMENT", 89, 91], ["anakinra", "TREATMENT", 104, 112], ["the multiple cytokines blocking JAK1", "TREATMENT", 118, 154], ["baricitinib", "TREATMENT", 167, 178]]], ["The recently published series on the JAK/STAT inhibitor ruxolitinib (rux) add another smart drug to the armamentarium against an array of inflammatory cytokines [2, 3] .", [["ruxolitinib", "CHEMICAL", 56, 67], ["rux", "CHEMICAL", 69, 72], ["ruxolitinib", "CHEMICAL", 56, 67], ["JAK", "GENE_OR_GENE_PRODUCT", 37, 40], ["STAT", "GENE_OR_GENE_PRODUCT", 41, 45], ["ruxolitinib", "SIMPLE_CHEMICAL", 56, 67], ["rux", "SIMPLE_CHEMICAL", 69, 72], ["JAK", "PROTEIN", 37, 40], ["inflammatory cytokines", "PROTEIN", 138, 160], ["the JAK/STAT inhibitor ruxolitinib", "TREATMENT", 33, 67], ["inflammatory cytokines", "PROBLEM", 138, 160], ["inflammatory", "OBSERVATION", 138, 150]]], ["Rux is approved for treatment of the myeloproliferative neoplasias polycythaemia vera and primary or secondary myelofibrosis as well as FDA-approved for glucocorticoid-refractory graft-versus-host disease.", [["myeloproliferative neoplasias", "ANATOMY", 37, 66], ["primary", "ANATOMY", 90, 97], ["myelofibrosis", "ANATOMY", 111, 124], ["graft", "ANATOMY", 179, 184], ["Rux", "CHEMICAL", 0, 3], ["myeloproliferative neoplasias", "DISEASE", 37, 66], ["polycythaemia vera", "DISEASE", 67, 85], ["myelofibrosis", "DISEASE", 111, 124], ["graft-versus-host disease", "DISEASE", 179, 204], ["glucocorticoid", "SIMPLE_CHEMICAL", 153, 167], ["graft", "TISSUE", 179, 184], ["treatment", "TREATMENT", 20, 29], ["the myeloproliferative neoplasias polycythaemia vera", "PROBLEM", 33, 85], ["secondary myelofibrosis", "PROBLEM", 101, 124], ["FDA", "TEST", 136, 139], ["glucocorticoid", "TREATMENT", 153, 167], ["refractory graft", "TREATMENT", 168, 184], ["host disease", "PROBLEM", 192, 204], ["myeloproliferative neoplasias polycythaemia vera", "OBSERVATION", 37, 85], ["secondary myelofibrosis", "OBSERVATION", 101, 124], ["refractory", "OBSERVATION_MODIFIER", 168, 178], ["graft", "OBSERVATION", 179, 184], ["host disease", "OBSERVATION", 192, 204]]], ["It also shows convincing efficacy in refractory secondary hemophagocytic lymphohistiocytosis (sHLH), another subtype of hyperferritinemic inflammation syndromes.", [["sHLH", "ANATOMY", 94, 98], ["hemophagocytic lymphohistiocytosis", "DISEASE", 58, 92], ["sHLH", "DISEASE", 94, 98], ["inflammation", "DISEASE", 138, 150], ["sHLH", "CANCER", 94, 98], ["refractory secondary hemophagocytic lymphohistiocytosis", "PROBLEM", 37, 92], ["hyperferritinemic inflammation syndromes", "PROBLEM", 120, 160], ["refractory", "OBSERVATION_MODIFIER", 37, 47], ["secondary", "OBSERVATION_MODIFIER", 48, 57], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 58, 92], ["subtype", "OBSERVATION_MODIFIER", 109, 116], ["hyperferritinemic inflammation syndromes", "OBSERVATION", 120, 160]]], ["In this issue of Acta Haematologica, Rojas and Sarmiento [4] from Chile report on 3 patients with progressive COVID-19 successfully treated with rux 10 mg b.i.d., thereby adding anecdotal evidence to the list of positive reports on rux in COVID-19 patients with moderate or severe disease.", [["COVID", "DISEASE", 110, 115], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 248, 256], ["progressive COVID", "PROBLEM", 98, 115], ["rux", "TREATMENT", 145, 148], ["moderate or severe disease", "PROBLEM", 262, 288], ["moderate", "OBSERVATION_MODIFIER", 262, 270], ["severe", "OBSERVATION_MODIFIER", 274, 280], ["disease", "OBSERVATION", 281, 288]]], ["Of note, 2 of the 3 patients suffered from COVID-19, while actively treated for (1) acute lymphoblastic leukaemia on the augmented BFM protocol, consolidation 2 (vincristine, methotrexate, PEG-asparaginase) or (2) multiple myeloma on induction treatment, second week (bortezomib, cyclophosphamide, and dexamethasone).", [["acute lymphoblastic leukaemia", "ANATOMY", 84, 113], ["myeloma", "ANATOMY", 223, 230], ["acute lymphoblastic leukaemia", "DISEASE", 84, 113], ["vincristine", "CHEMICAL", 162, 173], ["methotrexate", "CHEMICAL", 175, 187], ["PEG-asparaginase", "CHEMICAL", 189, 205], ["multiple myeloma", "DISEASE", 214, 230], ["bortezomib", "CHEMICAL", 268, 278], ["cyclophosphamide", "CHEMICAL", 280, 296], ["dexamethasone", "CHEMICAL", 302, 315], ["vincristine", "CHEMICAL", 162, 173], ["methotrexate", "CHEMICAL", 175, 187], ["PEG", "CHEMICAL", 189, 192], ["bortezomib", "CHEMICAL", 268, 278], ["cyclophosphamide", "CHEMICAL", 280, 296], ["dexamethasone", "CHEMICAL", 302, 315], ["patients", "ORGANISM", 20, 28], ["acute lymphoblastic leukaemia", "CANCER", 84, 113], ["vincristine", "SIMPLE_CHEMICAL", 162, 173], ["methotrexate", "SIMPLE_CHEMICAL", 175, 187], ["PEG-asparaginase", "SIMPLE_CHEMICAL", 189, 205], ["myeloma", "CANCER", 223, 230], ["bortezomib", "SIMPLE_CHEMICAL", 268, 278], ["cyclophosphamide", "SIMPLE_CHEMICAL", 280, 296], ["dexamethasone", "SIMPLE_CHEMICAL", 302, 315], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 43, 48], ["acute lymphoblastic leukaemia", "PROBLEM", 84, 113], ["the augmented BFM protocol", "TREATMENT", 117, 143], ["consolidation", "PROBLEM", 145, 158], ["vincristine", "TREATMENT", 162, 173], ["methotrexate", "TREATMENT", 175, 187], ["PEG-asparaginase", "TREATMENT", 189, 205], ["multiple myeloma", "PROBLEM", 214, 230], ["induction treatment", "TREATMENT", 234, 253], ["bortezomib", "TREATMENT", 268, 278], ["cyclophosphamide", "TREATMENT", 280, 296], ["dexamethasone", "TREATMENT", 302, 315], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["lymphoblastic leukaemia", "OBSERVATION", 90, 113], ["consolidation", "OBSERVATION", 145, 158], ["multiple", "OBSERVATION_MODIFIER", 214, 222], ["myeloma", "OBSERVATION", 223, 230]]], ["As immunosuppression with dex has been shown to prolong life in COVID-19, both patients actively immunosuppressed by anti-lymphoproliferative protocols challenge the intuitive view that lymphocytes/macrophages causing severe COVID-19 pneumonia should have been blocked by chemotherapy and dex [4] .", [["lymphocytes", "ANATOMY", 186, 197], ["macrophages", "ANATOMY", 198, 209], ["dex", "CHEMICAL", 26, 29], ["pneumonia", "DISEASE", 234, 243], ["dex", "SIMPLE_CHEMICAL", 26, 29], ["COVID-19", "CELL", 64, 72], ["patients", "ORGANISM", 79, 87], ["lymphocytes", "CELL", 186, 197], ["macrophages", "CELL", 198, 209], ["lymphocytes", "CELL_TYPE", 186, 197], ["macrophages", "CELL_TYPE", 198, 209], ["patients", "SPECIES", 79, 87], ["immunosuppression", "TREATMENT", 3, 20], ["dex", "TREATMENT", 26, 29], ["COVID", "TEST", 64, 69], ["anti-lymphoproliferative protocols", "TREATMENT", 117, 151], ["lymphocytes", "PROBLEM", 186, 197], ["macrophages", "PROBLEM", 198, 209], ["severe COVID", "PROBLEM", 218, 230], ["pneumonia", "PROBLEM", 234, 243], ["chemotherapy and dex", "TREATMENT", 272, 292], ["severe", "OBSERVATION_MODIFIER", 218, 224], ["pneumonia", "OBSERVATION", 234, 243]]], ["The reported patients worsened clinically despite active immunosuppression, but responded to rux, a JAK1/2 inhibitor suppressing IL-1\u03b2, IL-6, and TNF-\u03b1 besides other proinflammatory cytokines [2] .", [["patients", "ORGANISM", 13, 21], ["JAK1/2", "GENE_OR_GENE_PRODUCT", 100, 106], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 129, 134], ["IL-6", "GENE_OR_GENE_PRODUCT", 136, 140], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 146, 151], ["JAK1", "PROTEIN", 100, 104], ["IL-1\u03b2, IL-6", "PROTEIN", 129, 140], ["TNF", "PROTEIN", 146, 149], ["proinflammatory cytokines", "PROTEIN", 166, 191], ["patients", "SPECIES", 13, 21], ["active immunosuppression", "TREATMENT", 50, 74], ["rux", "TEST", 93, 96], ["a JAK1", "TEST", 98, 104], ["IL", "TEST", 129, 131], ["IL", "TEST", 136, 138], ["TNF", "TEST", 146, 149], ["worsened", "OBSERVATION_MODIFIER", 22, 30], ["active", "OBSERVATION_MODIFIER", 50, 56], ["immunosuppression", "OBSERVATION", 57, 74]]], ["Given the favourable results for low-dose dex recently published by the British RE-COVERY group, this observation deserves special consideration: dex in the recovery cohort worked best in moderate/severe COVID-19 but was less effective in patients not requiring oxygen support [1] .", [["dex", "CHEMICAL", 42, 45], ["dex", "CHEMICAL", 146, 149], ["oxygen", "CHEMICAL", 262, 268], ["oxygen", "CHEMICAL", 262, 268], ["patients", "ORGANISM", 239, 247], ["oxygen", "SIMPLE_CHEMICAL", 262, 268], ["patients", "SPECIES", 239, 247], ["low-dose dex", "TREATMENT", 33, 45], ["dex", "TREATMENT", 146, 149], ["moderate/severe COVID", "PROBLEM", 188, 209], ["oxygen support", "TREATMENT", 262, 276]]], ["Whereas glucocorticoids are known to suppress inflammation via multiple mechanisms, the targeted approach by rux mightas shown in glucocorticoid-treated graft-versus-host disease [5] -rescue an obvious failure to do so (as shown in the myeloma patient).", [["graft", "ANATOMY", 153, 158], ["myeloma", "ANATOMY", 236, 243], ["glucocorticoids", "CHEMICAL", 8, 23], ["inflammation", "DISEASE", 46, 58], ["myeloma", "DISEASE", 236, 243], ["glucocorticoids", "SIMPLE_CHEMICAL", 8, 23], ["glucocorticoid", "SIMPLE_CHEMICAL", 130, 144], ["graft-versus-host", "ORGANISM", 153, 170], ["myeloma", "CANCER", 236, 243], ["patient", "ORGANISM", 244, 251], ["patient", "SPECIES", 244, 251], ["glucocorticoids", "TREATMENT", 8, 23], ["inflammation", "PROBLEM", 46, 58], ["the targeted approach", "TREATMENT", 84, 105], ["glucocorticoid-treated graft", "TREATMENT", 130, 158], ["host disease", "PROBLEM", 166, 178], ["an obvious failure", "PROBLEM", 191, 209], ["inflammation", "OBSERVATION", 46, 58], ["glucocorticoid", "ANATOMY", 130, 144], ["host disease", "OBSERVATION", 166, 178], ["obvious", "OBSERVATION_MODIFIER", 194, 201], ["failure", "OBSERVATION", 202, 209], ["myeloma", "OBSERVATION", 236, 243]]], ["Timing (hitting the protective early IFN-I response vs. suppressing the damaging late IFN-response) might also play a role in the reported pa-tients, who were on strong immunosuppression during the viral replication phase.", [["IFN-I", "GENE_OR_GENE_PRODUCT", 37, 42], ["IFN", "PROTEIN", 37, 40], ["IFN", "PROTEIN", 86, 89], ["strong immunosuppression", "TREATMENT", 162, 186]]], ["As such, this report urges us to reflect on future trial designs aiming to retrieve the anti-inflammatory molecule potentially outperforming dex, which -until now -is SOC in hyperinflammatory COVID-19 patients.", [["dex", "SIMPLE_CHEMICAL", 141, 144], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["future trial designs", "TREATMENT", 44, 64], ["the anti-inflammatory molecule", "TREATMENT", 84, 114], ["dex", "TREATMENT", 141, 144]]], ["Should we use laboratory or combined clinical inflammation scores to define optimal timing for medical treatment of cytokine release as proposed by a currently active trial using the PENN score for CRS stage classification (NCT04374149) or the newly developed COVID Inflammation Score (CIS) that is now prospectively evaluated by the RuxCoFlam trial (NCT04338958) [3] .", [["inflammation", "DISEASE", 46, 58], ["cytokine", "PROTEIN", 116, 124], ["combined clinical inflammation scores", "PROBLEM", 28, 65], ["medical treatment of cytokine release", "TREATMENT", 95, 132], ["CRS stage classification", "PROBLEM", 198, 222], ["COVID Inflammation Score", "PROBLEM", 260, 284], ["Inflammation", "OBSERVATION", 266, 278]]], ["Others used the HScore assisting in detection of patients with high probability for sHLH [6] .", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["The HScore, however, may fall short in early detection of patients at risk, as sHLH is a very rare complication of extremely severe COVID-19.", [["sHLH", "DISEASE", 79, 83], ["COVID-19", "CHEMICAL", 132, 140], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["a very rare complication", "PROBLEM", 87, 111], ["extremely severe COVID", "PROBLEM", 115, 137]]], ["Most patients may benefit from early intervention to avoid extreme inflammation, ARDS, and multiorgan failure [3] .", [["multiorgan", "ANATOMY", 91, 101], ["inflammation", "DISEASE", 67, 79], ["ARDS", "DISEASE", 81, 85], ["multiorgan failure", "DISEASE", 91, 109], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["early intervention", "TREATMENT", 31, 49], ["extreme inflammation", "PROBLEM", 59, 79], ["ARDS", "PROBLEM", 81, 85], ["multiorgan failure", "PROBLEM", 91, 109], ["inflammation", "OBSERVATION", 67, 79], ["ARDS", "OBSERVATION", 81, 85], ["multiorgan failure", "OBSERVATION", 91, 109]]], ["On the other hand, the recovery trial sets a cautionary signal not to suppress the immune defence at too early stages of the disease, to allow recovery without unnecessary and potentially harmful treatment.", [["the immune defence", "PROBLEM", 79, 97], ["the disease", "PROBLEM", 121, 132], ["harmful treatment", "TREATMENT", 188, 205], ["disease", "OBSERVATION", 125, 132]]], ["It is tempting to speculate on a future welldefined cytokine profile guiding individually tailored anti-inflammatory treatment.", [["cytokine", "PROTEIN", 52, 60], ["a future welldefined cytokine profile", "TREATMENT", 31, 68], ["tailored anti-inflammatory treatment", "TREATMENT", 90, 126], ["anti-inflammatory treatment", "OBSERVATION", 99, 126]]]], "1e45cd5feb7928bbc8bcd524d9c6b7adeae08a6b": [["SummaryBackground Whether the patients with COVID-19 infected by SARS-CoV-2 would commonly develop acute renal function damage is a problem worthy of clinical attention.", [["renal", "ANATOMY", 105, 110], ["COVID-19", "CHEMICAL", 44, 52], ["SARS", "DISEASE", 65, 69], ["acute renal function damage", "DISEASE", 99, 126], ["patients", "ORGANISM", 30, 38], ["COVID-19", "ORGANISM", 44, 52], ["SARS-CoV-2", "ORGANISM", 65, 75], ["renal", "ORGAN", 105, 110], ["patients", "SPECIES", 30, 38], ["SARS-CoV", "SPECIES", 65, 73], ["COVID", "TEST", 44, 49], ["SARS", "PROBLEM", 65, 69], ["acute renal function damage", "PROBLEM", 99, 126], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["renal", "ANATOMY", 105, 110], ["function", "OBSERVATION", 111, 119]]], ["This study aimed to explore the effects of SARS-CoV-2 infection on renal function through analyzing the clinical data of 116 hospitalized COVID-19-confirmed patients.SummaryMethods 116 hospitalized COVID-19-confirmed patients enrolled in this study were hospitalized in the Department of Infectious Diseases, Renmin Hospital of Wuhan University from January 14 to February 13, 2020.", [["renal", "ANATOMY", 67, 72], ["infection", "DISEASE", 54, 63], ["Infectious Diseases", "DISEASE", 288, 307], ["SARS-CoV-2", "ORGANISM", 43, 53], ["renal", "ORGAN", 67, 72], ["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 217, 225], ["SARS-CoV", "SPECIES", 43, 51], ["This study", "TEST", 0, 10], ["SARS", "PROBLEM", 43, 47], ["CoV-2 infection", "PROBLEM", 48, 63], ["renal function", "TEST", 67, 81], ["the clinical data", "TEST", 100, 117], ["COVID", "TEST", 138, 143], ["COVID", "TEST", 198, 203], ["this study", "TEST", 238, 248], ["infection", "OBSERVATION", 54, 63], ["renal", "ANATOMY", 67, 72], ["Infectious", "OBSERVATION", 288, 298]]], ["The recorded information includes demographic data, medical history, contact history, potential comorbidities, symptoms, signs, laboratory test results, chest computer tomography (CT) scans, and treatment measures.", [["potential comorbidities", "PROBLEM", 86, 109], ["symptoms", "PROBLEM", 111, 119], ["laboratory test", "TEST", 128, 143], ["chest computer tomography", "TEST", 153, 178], ["CT) scans", "TEST", 180, 189], ["treatment measures", "TREATMENT", 195, 213], ["chest", "ANATOMY", 153, 158]]], ["SARS-CoV-2 RNA in 53 urine sediments of enrolled patients was examined by real-time RT-PCR.SummaryFindings 12 (10.8%) and 8 (7.2%) patients showed mild elevation of blood urea nitrogen or creatinine, and trace or 1+ albuminuria respectively in 111 COVID-19-confirmed patients without basic kidney disease.", [["urine sediments", "ANATOMY", 21, 36], ["blood", "ANATOMY", 165, 170], ["kidney", "ANATOMY", 290, 296], ["SARS", "DISEASE", 0, 4], ["blood urea nitrogen", "CHEMICAL", 165, 184], ["creatinine", "CHEMICAL", 188, 198], ["albuminuria", "DISEASE", 216, 227], ["kidney disease", "DISEASE", 290, 304], ["urea", "CHEMICAL", 171, 175], ["nitrogen", "CHEMICAL", 176, 184], ["creatinine", "CHEMICAL", 188, 198], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["urine", "ORGANISM_SUBSTANCE", 21, 26], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 131, 139], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["urea", "SIMPLE_CHEMICAL", 171, 175], ["creatinine", "SIMPLE_CHEMICAL", 188, 198], ["patients", "ORGANISM", 267, 275], ["kidney", "ORGAN", 290, 296], ["SARS-CoV-2 RNA", "RNA", 0, 14], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 267, 275], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["urine sediments", "TEST", 21, 36], ["SummaryFindings", "TEST", 91, 106], ["mild elevation of blood urea nitrogen", "PROBLEM", 147, 184], ["creatinine", "TEST", 188, 198], ["albuminuria", "TEST", 216, 227], ["COVID", "TEST", 248, 253], ["basic kidney disease", "PROBLEM", 284, 304], ["mild", "OBSERVATION_MODIFIER", 147, 151], ["elevation", "OBSERVATION", 152, 161], ["without", "UNCERTAINTY", 276, 283], ["kidney", "ANATOMY", 290, 296], ["disease", "OBSERVATION", 297, 304]]], ["In addition, 5 patients with chronic renal failure (CRF) were undergone regular continuous renal replacement therapy (CRRT) were confirmed infection of SARS-CoV-2, and diagnosed as COVID-19.", [["renal", "ANATOMY", 37, 42], ["renal", "ANATOMY", 91, 96], ["chronic renal failure", "DISEASE", 29, 50], ["CRF", "DISEASE", 52, 55], ["infection", "DISEASE", 139, 148], ["SARS", "DISEASE", 152, 156], ["patients", "ORGANISM", 15, 23], ["renal", "ORGAN", 37, 42], ["renal", "ORGAN", 91, 96], ["patients", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 152, 160], ["chronic renal failure", "PROBLEM", 29, 50], ["CRF)", "PROBLEM", 52, 56], ["regular continuous renal replacement therapy", "TREATMENT", 72, 116], ["CRRT", "TREATMENT", 118, 122], ["infection", "PROBLEM", 139, 148], ["SARS", "PROBLEM", 152, 156], ["CoV", "TEST", 157, 160], ["COVID", "TEST", 181, 186], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["renal", "ANATOMY", 37, 42], ["failure", "OBSERVATION", 43, 50], ["renal", "ANATOMY", 91, 96], ["replacement", "OBSERVATION", 97, 108]]], ["Beside the treatment of COVID-19, CRRT was also applied three times weekly.", [["COVID", "TREATMENT", 24, 29], ["CRRT", "TREATMENT", 34, 38]]], ["The course of treatment, the renal function indicators showed stable, without exacerbation of CRF, and pulmonary inflammation was gradually absorbed.", [["renal", "ANATOMY", 29, 34], ["pulmonary", "ANATOMY", 103, 112], ["CRF", "DISEASE", 94, 97], ["pulmonary inflammation", "DISEASE", 103, 125], ["renal", "ORGAN", 29, 34], ["pulmonary", "ORGAN", 103, 112], ["treatment", "TREATMENT", 14, 23], ["the renal function indicators", "TEST", 25, 54], ["exacerbation", "PROBLEM", 78, 90], ["CRF", "PROBLEM", 94, 97], ["pulmonary inflammation", "PROBLEM", 103, 125], ["renal", "ANATOMY", 29, 34], ["stable", "OBSERVATION_MODIFIER", 62, 68], ["without", "UNCERTAINTY", 70, 77], ["CRF", "OBSERVATION", 94, 97], ["pulmonary", "ANATOMY", 103, 112], ["inflammation", "OBSERVATION", 113, 125]]], ["All 5 patients with CRF were survived.", [["CRF", "DISEASE", 20, 23], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["CRF", "PROBLEM", 20, 23]]], ["Moreover, SARS-CoV-2 RNA in urine sediments was positive only in 3 patients from 48 cases without renal illness before, and one patient had a positive for SARS-CoV-2 ORF 1ab from 5 cases with CRF.IntroductionIn December 2019, an acute respiratory infectious disease caused by a novel coronavirus occurred in Wuhan, Hubei Province, China, which is now officially named as \"2019 coronavirus disease \" by the WHO [1] [2] [3] .", [["urine sediments", "ANATOMY", 28, 43], ["renal", "ANATOMY", 98, 103], ["respiratory", "ANATOMY", 235, 246], ["renal illness", "DISEASE", 98, 111], ["CRF", "DISEASE", 192, 195], ["respiratory infectious disease", "DISEASE", 235, 265], ["coronavirus", "DISEASE", 284, 295], ["coronavirus disease", "DISEASE", 377, 396], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["urine sediments", "ORGANISM_SUBSTANCE", 28, 43], ["patients", "ORGANISM", 67, 75], ["renal", "ORGAN", 98, 103], ["patient", "ORGANISM", 128, 135], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 155, 165], ["CRF", "GENE_OR_GENE_PRODUCT", 192, 195], ["coronavirus", "ORGANISM", 284, 295], ["SARS-CoV-2 RNA", "RNA", 10, 24], ["SARS-CoV-2 ORF 1", "DNA", 155, 171], ["patients", "SPECIES", 67, 75], ["patient", "SPECIES", 128, 135], ["coronavirus", "SPECIES", 284, 295], ["SARS-CoV", "SPECIES", 10, 18], ["SARS-CoV", "SPECIES", 155, 163], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["urine sediments", "TEST", 28, 43], ["renal illness", "PROBLEM", 98, 111], ["SARS", "PROBLEM", 155, 159], ["CoV", "TEST", 160, 163], ["CRF", "PROBLEM", 192, 195], ["an acute respiratory infectious disease", "PROBLEM", 226, 265], ["a novel coronavirus", "PROBLEM", 276, 295], ["renal", "ANATOMY", 98, 103], ["illness", "OBSERVATION", 104, 111], ["CRF", "OBSERVATION", 192, 195], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["respiratory", "ANATOMY", 235, 246], ["infectious", "OBSERVATION", 247, 257], ["coronavirus", "OBSERVATION", 284, 295]]], ["The disease has spread rapidly from Wuhan to other regions in China.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["spread", "OBSERVATION_MODIFIER", 16, 22], ["rapidly", "OBSERVATION_MODIFIER", 23, 30], ["China", "ANATOMY", 62, 67]]], ["As of 24:00 on February 13, 2020, a total of 63,851 COVID-19-confirmed cases were reported in China [4] .", [["COVID", "TEST", 52, 57]]], ["Internationally, cases have been reported in 24 countries and 5 continents [5] .IntroductionOn January 3, 2020, a novel coronavirus was identified in a bronchial alveolar lavage fluid sample from a patient in Wuhan and confirmed to be the cause of COVID-19 [6] .", [["bronchial alveolar lavage fluid sample", "ANATOMY", 152, 190], ["COVID-19", "CHEMICAL", 248, 256], ["coronavirus", "ORGANISM", 120, 131], ["bronchial alveolar lavage", "ORGANISM_SUBSTANCE", 152, 177], ["patient", "ORGANISM", 198, 205], ["patient", "SPECIES", 198, 205], ["a novel coronavirus", "PROBLEM", 112, 131], ["a bronchial alveolar lavage fluid sample", "TEST", 150, 190], ["COVID", "TEST", 248, 253], ["bronchial", "ANATOMY", 152, 161], ["alveolar", "ANATOMY_MODIFIER", 162, 170]]], ["Whole genome sequencing and systematic analysis showed that this novel coronavirus is a distinct clade from beta coronavirus associated with human severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [6] , which was officially named \"SARS-CoV-2\" by WHO now.", [["beta coronavirus", "DISEASE", 108, 124], ["acute respiratory syndrome", "DISEASE", 154, 180], ["SARS", "DISEASE", 182, 186], ["Middle East respiratory syndrome", "DISEASE", 192, 224], ["SARS", "DISEASE", 266, 270], ["coronavirus", "ORGANISM", 71, 82], ["beta coronavirus", "ORGANISM", 108, 124], ["human", "ORGANISM", 141, 146], ["coronavirus", "SPECIES", 71, 82], ["coronavirus", "SPECIES", 113, 124], ["human", "SPECIES", 141, 146], ["beta coronavirus", "SPECIES", 108, 124], ["human severe acute respiratory syndrome (SARS)", "SPECIES", 141, 187], ["Middle East respiratory syndrome (MERS)", "SPECIES", 192, 231], ["Whole genome sequencing", "TEST", 0, 23], ["systematic analysis", "TEST", 28, 47], ["this novel coronavirus", "PROBLEM", 60, 82], ["a distinct clade", "PROBLEM", 86, 102], ["beta coronavirus", "PROBLEM", 108, 124], ["human severe acute respiratory syndrome", "PROBLEM", 141, 180], ["SARS)", "PROBLEM", 182, 187], ["Middle East respiratory syndrome", "PROBLEM", 192, 224], ["beta coronavirus", "OBSERVATION", 108, 124], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["respiratory syndrome", "OBSERVATION", 160, 180], ["Middle", "ANATOMY_MODIFIER", 192, 198], ["respiratory syndrome", "OBSERVATION", 204, 224]]], ["Although the origin of SARS-CoV-2 is still being investigated, current evidence suggests it was transmitted to humans through the spread of wild animals illegally sold in Huanan Seafood Wholesale Market [7] .", [["SARS", "DISEASE", 23, 27], ["SARS-CoV-2", "ORGANISM", 23, 33], ["humans", "ORGANISM", 111, 117], ["humans", "SPECIES", 111, 117], ["SARS-CoV", "SPECIES", 23, 31], ["humans", "SPECIES", 111, 117], ["SARS", "PROBLEM", 23, 27], ["SARS", "OBSERVATION", 23, 27]]], ["Case reports have confirmed the interpersonal transmission of SARS-CoV-2 [8] .", [["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 62, 72], ["SARS-CoV", "SPECIES", 62, 70]]], ["Currently, there are no specific treatments or vaccines for COVID-19.", [["specific treatments", "TREATMENT", 24, 43], ["vaccines", "TREATMENT", 47, 55], ["COVID", "TEST", 60, 65], ["no", "UNCERTAINTY", 21, 23]]], ["The patient's clinical manifestations included fever, unproductive cough, dyspnea, myalgia, fatigue, normal or decreased white blood cell count, and imaging evidence of pneumonia [9] .", [["white blood cell", "ANATOMY", 121, 137], ["fever", "DISEASE", 47, 52], ["cough", "DISEASE", 67, 72], ["dyspnea", "DISEASE", 74, 81], ["myalgia", "DISEASE", 83, 90], ["fatigue", "DISEASE", 92, 99], ["pneumonia", "DISEASE", 169, 178], ["patient", "ORGANISM", 4, 11], ["blood cell", "CELL", 127, 137], ["patient", "SPECIES", 4, 11], ["The patient's clinical manifestations", "PROBLEM", 0, 37], ["fever", "PROBLEM", 47, 52], ["unproductive cough", "PROBLEM", 54, 72], ["dyspnea", "PROBLEM", 74, 81], ["myalgia", "PROBLEM", 83, 90], ["fatigue", "PROBLEM", 92, 99], ["decreased white blood cell count", "PROBLEM", 111, 143], ["pneumonia", "PROBLEM", 169, 178], ["myalgia", "OBSERVATION", 83, 90], ["evidence of", "UNCERTAINTY", 157, 168], ["pneumonia", "OBSERVATION", 169, 178]]], ["Wang et al. reported in 138 hospitalized COVID-19-confirmed cases, presumed hospital-related transmission of SARS-CoV-2 was suspected in 41% of patients, 26% of patients received ICU care, and mortality was 4.3% [10] .", [["SARS", "DISEASE", 109, 113], ["SARS-CoV-2", "ORGANISM", 109, 119], ["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 161, 169], ["SARS-CoV", "SPECIES", 109, 117], ["COVID", "TEST", 41, 46], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["ICU care", "TREATMENT", 179, 187]]], ["In this study, the clinical data of 116 hospitalized COVID-19-confirmed patients were analyzed, and the effects of SARS-CoV-2 infection on renal function were explored.Study design and participantsRenmin Hospital of Wuhan University is located in Wuhan City, Hubei Province, an area where COVID-19 is endemic.", [["renal", "ANATOMY", 139, 144], ["SARS", "DISEASE", 115, 119], ["infection", "DISEASE", 126, 135], ["patients", "ORGANISM", 72, 80], ["SARS-CoV-2", "ORGANISM", 115, 125], ["renal", "ORGAN", 139, 144], ["participants", "ORGANISM", 185, 197], ["patients", "SPECIES", 72, 80], ["participants", "SPECIES", 185, 197], ["this study", "TEST", 3, 13], ["the clinical data", "TEST", 15, 32], ["COVID", "TEST", 53, 58], ["SARS", "PROBLEM", 115, 119], ["CoV", "PROBLEM", 120, 123], ["2 infection", "PROBLEM", 124, 135], ["COVID", "TEST", 289, 294], ["endemic", "PROBLEM", 301, 308], ["infection", "OBSERVATION", 126, 135], ["renal", "ANATOMY", 139, 144]]], ["In this study, 116 COVID-19-confirmed patients were enrolled, who were hospitalized in the Department of Infectious Diseases, Renmin Hospital of Wuhan University from January 14 to February 13, 2020 (before January 20, they were diagnosed as unknown origin viral pneumonia).", [["Infectious Diseases", "DISEASE", 105, 124], ["viral pneumonia", "DISEASE", 257, 272], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["this study", "TEST", 3, 13], ["COVID", "TEST", 19, 24], ["viral pneumonia", "PROBLEM", 257, 272], ["Infectious", "OBSERVATION", 105, 115], ["pneumonia", "OBSERVATION", 263, 272]]], ["Oral consent was obtained from all patients.", [["Oral", "ANATOMY", 0, 4], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["A confirmed-diagnosis of all COVID-19 patients participating in this study was made according to the WHO's interim guidelines [11] .", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["all COVID", "TEST", 25, 34], ["this study", "TEST", 64, 74]]], ["This study was approved by the Institutional Ethics Committee of Renmin Hospital of Wuhan University.Nucleic acid detection of SARS-CoV-2All COVID-19 patients enrolled in this study were laboratory-confirmed cases, which were identified with nucleic acid detection of SARS-CoV-2 from a throat swab samples using reverse transcription-polymerase chain reaction (RT-PCR).", [["throat swab samples", "ANATOMY", 286, 305], ["Nucleic acid", "CHEMICAL", 101, 113], ["nucleic acid", "CHEMICAL", 242, 254], ["SARS-CoV-2All COVID", "ORGANISM", 127, 146], ["patients", "ORGANISM", 150, 158], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 268, 278], ["patients", "SPECIES", 150, 158], ["SARS-CoV-2All", "SPECIES", 127, 140], ["SARS-CoV", "SPECIES", 268, 276], ["This study", "TEST", 0, 10], ["Nucleic acid detection", "TEST", 101, 123], ["SARS", "PROBLEM", 127, 131], ["CoV", "TEST", 132, 135], ["this study", "TEST", 171, 181], ["nucleic acid detection", "TEST", 242, 264], ["SARS", "PROBLEM", 268, 272], ["CoV", "TEST", 273, 276], ["a throat swab samples", "TEST", 284, 305], ["reverse transcription", "TEST", 312, 333], ["polymerase chain reaction", "PROBLEM", 334, 359], ["RT-PCR", "TEST", 361, 367], ["throat", "ANATOMY", 286, 292]]], ["The criteria for the confirmed-diagnosis of SARS-CoV-2 was that at least one gene site was amplified to be positive for nucleocapsid protein (NP) gene and open reading frame (ORF) 1ab gene.", [["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "ORGANISM", 44, 54], ["nucleocapsid protein (NP)", "GENE_OR_GENE_PRODUCT", 120, 145], ["open reading frame (ORF) 1", "GENE_OR_GENE_PRODUCT", 155, 181], ["nucleocapsid protein (NP) gene", "DNA", 120, 150], ["open reading frame (ORF) 1ab gene", "DNA", 155, 188], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "PROBLEM", 44, 48], ["nucleocapsid protein (NP) gene", "TREATMENT", 120, 150]]], ["In brief, the throat swab was put into a collection tube containing 150\u03bcl viral preservation solution, and the total RNA was extracted within 2h with the respiratory sample RNA separation Kit (Zhongzhi, Wuhan).", [["throat swab", "ANATOMY", 14, 25], ["throat", "ORGANISM", 14, 20], ["swab", "ORGANISM_SUBSTANCE", 21, 25], ["tube", "TISSUE", 52, 56], ["total RNA", "RNA", 111, 120], ["the throat swab", "TEST", 10, 25], ["a collection tube", "TREATMENT", 39, 56], ["150\u03bcl viral preservation solution", "TREATMENT", 68, 101], ["the total RNA", "TREATMENT", 107, 120], ["throat", "ANATOMY", 14, 20]]], ["The suspension All rights reserved.", [["The suspension All rights", "TREATMENT", 0, 25], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["No reuse allowed without permission.Nucleic acid detection of SARS-CoV-2author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Nucleic acid detection of SARS-CoV-2The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.", [["Nucleic acid", "CHEMICAL", 36, 48], ["SARS", "DISEASE", 62, 66], ["Nucleic acid", "CHEMICAL", 159, 171], ["SARS", "DISEASE", 185, 189], ["SARS-CoV", "SPECIES", 185, 193], ["Nucleic acid detection", "TEST", 36, 58], ["SARS", "PROBLEM", 62, 66], ["Nucleic acid detection", "TEST", 159, 181], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 103, 106]]], ["19.20025288 doi: medRxiv preprint was used for RT-PCR assay of SARS-CoV-2 RNA.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 63, 73], ["SARS-CoV-2 RNA", "RNA", 63, 77], ["SARS-CoV", "SPECIES", 63, 71], ["medRxiv preprint", "TREATMENT", 17, 33], ["RT-PCR assay", "TEST", 47, 59], ["SARS", "PROBLEM", 63, 67], ["CoV", "TEST", 68, 71]]], ["Two target genes, including NP and ORF1ab, were simultaneously amplified and tested during the real-time RT-PCR assay.", [["NP", "GENE_OR_GENE_PRODUCT", 28, 30], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 35, 41], ["target genes", "DNA", 4, 16], ["NP", "DNA", 28, 30], ["ORF1ab", "DNA", 35, 41], ["NP and ORF1ab", "TREATMENT", 28, 41]]], ["Target 1 (NP): forward primer GGGGAACTTCTCCTGCTAGAAT; reverse primer CAGACATTTTGCTCTC AAGCTG; and the probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'.", [["Target 1 (NP): forward primer", "DNA", 0, 29], ["reverse primer", "DNA", 54, 68], ["probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3", "DNA", 102, 143], ["forward primer GGGGAACTTCTCCTGCTAGAAT", "TREATMENT", 15, 52], ["reverse primer CAGACATTTTGCTCTC AAGCTG", "TREATMENT", 54, 92], ["the probe", "TREATMENT", 98, 107]]], ["Target 2 (ORF1ab): forward primer CCCTGTGGGTTTTACACTTAA; reverse primer ACGATTGTGC ATCAGCTGA; and the probe 5'-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1 -3'.Nucleic acid detection of SARS-CoV-2The real-time RT-PCR assay was performed using a 2019-nCoV nucleic acid detection kit according to the manufacturer's protocol (Shanghai bio-germ Medical Technology Co Ltd).", [["nucleic acid", "CHEMICAL", 248, 260], ["ORF1ab", "DNA", 10, 16], ["forward primer", "DNA", 19, 33], ["reverse primer", "DNA", 57, 71], ["probe 5'-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1 -3", "DNA", 102, 151], ["SARS-CoV", "SPECIES", 179, 187], ["forward primer CCCTGTGGGTTTTACACTTAA", "TREATMENT", 19, 55], ["reverse primer ACGATTGTGC ATCAGCTGA", "TREATMENT", 57, 92], ["Nucleic acid detection", "TEST", 153, 175], ["SARS", "TEST", 179, 183], ["CoV", "TEST", 184, 187], ["PCR assay", "TEST", 206, 215], ["the manufacturer's protocol", "TREATMENT", 288, 315]]], ["Specific primers and probes for SARS-CoV-2 RNA detection were based on the recommendation by the National Institute for Viral Disease Control and Prevention (China) (http://ivdc.chinacdc.cn /kyjz/202001/t20200121_211337.html).Data collectionEpidemiological, clinical, laboratory, and radiological characteristics were recorded.", [["Viral Disease", "DISEASE", 120, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["Specific primers", "TEST", 0, 16], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["RNA detection", "TEST", 43, 56], ["Viral Disease Control", "TREATMENT", 120, 141]]], ["The patients' medical history as well as treatment and outcome data, were also obtained through data collection tables in electronic medical records.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["outcome data", "TEST", 55, 67]]], ["The recorded information includes demographic data, medical history, contact history, potential comorbidities, symptoms, signs, laboratory test results, chest computer tomography (CT) scans, kidney B-ultrasonic examination and treatment measures (i.e. antiviral therapy, glucocorticoid usage, breathing support, kidney replacement therapy).", [["kidney", "ANATOMY", 191, 197], ["kidney", "ANATOMY", 312, 318], ["kidney", "ORGAN", 191, 197], ["kidney", "ORGAN", 312, 318], ["potential comorbidities", "PROBLEM", 86, 109], ["symptoms", "PROBLEM", 111, 119], ["laboratory test", "TEST", 128, 143], ["chest computer tomography", "TEST", 153, 178], ["CT) scans", "TEST", 180, 189], ["kidney B-ultrasonic examination", "TEST", 191, 222], ["treatment measures", "TREATMENT", 227, 245], ["antiviral therapy", "TREATMENT", 252, 269], ["glucocorticoid usage", "TREATMENT", 271, 291], ["breathing support", "TREATMENT", 293, 310], ["kidney replacement therapy", "TREATMENT", 312, 338], ["chest", "ANATOMY", 153, 158], ["kidney", "ANATOMY", 191, 197], ["kidney", "ANATOMY", 312, 318]]], ["The onset date was defined as the date on which symptoms appear.", [["symptoms", "PROBLEM", 48, 56]]], ["Different clinical categories were defined for all COVID-19 patients participating in the study according to the WHO's interim guidelines, including Mild pneumonia, Severe pneumonia, and Acute Respiratory Distress Syndrome (ARDS) [11] .", [["pneumonia", "DISEASE", 154, 163], ["pneumonia", "DISEASE", 172, 181], ["Acute Respiratory Distress Syndrome", "DISEASE", 187, 222], ["ARDS", "DISEASE", 224, 228], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["the study", "TEST", 86, 95], ["Mild pneumonia", "PROBLEM", 149, 163], ["Severe pneumonia", "PROBLEM", 165, 181], ["Acute Respiratory Distress Syndrome", "PROBLEM", 187, 222], ["ARDS)", "PROBLEM", 224, 229], ["Mild", "OBSERVATION_MODIFIER", 149, 153], ["pneumonia", "OBSERVATION", 154, 163], ["Severe", "OBSERVATION_MODIFIER", 165, 171], ["pneumonia", "OBSERVATION", 172, 181], ["Acute", "OBSERVATION_MODIFIER", 187, 192], ["Respiratory Distress Syndrome", "OBSERVATION", 193, 222]]], ["Acute kidney injury was identified according to Kidney Disease: Improving Global Outcomes (KDIGO) [12] .Statistical analysisCategorical variables were described as frequency and percentage, and continuous variables were described as using mean, median, and interquartile range (IQR) values.", [["kidney", "ANATOMY", 6, 12], ["Kidney", "ANATOMY", 48, 54], ["Acute kidney injury", "DISEASE", 0, 19], ["Kidney Disease", "DISEASE", 48, 62], ["kidney", "ORGAN", 6, 12], ["Acute kidney injury", "PROBLEM", 0, 19], ["Kidney Disease", "PROBLEM", 48, 62], ["percentage", "TEST", 178, 188], ["kidney", "ANATOMY", 6, 12], ["injury", "OBSERVATION", 13, 19], ["Kidney", "ANATOMY", 48, 54], ["Disease", "OBSERVATION", 55, 62]]], ["When the data were normally distributed, independent t-tests were used to compare the mean of continuous variables.", [["independent t-tests", "TEST", 41, 60]]], ["Although Fisher's exact test was used with limited data, the \u03c7 2 test was used to compare the proportion of categorical variables.", [["Fisher's exact test", "TEST", 9, 28], ["the \u03c7 2 test", "TEST", 57, 69]]], ["All statistical analyses were performed using SPSS version 13.0 software.", [["All statistical analyses", "TEST", 0, 24], ["SPSS version", "TEST", 46, 58]]], ["A P value of less than 0.05 is statistically significant.Presenting CharacteristicsIn this study, the median age of 116 COVID-19-confirmed patients was 54 years (IQR, 38-69; range 20-95 years), of which 67 (57.8%) were male.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["A P value", "TEST", 0, 9], ["this study", "TEST", 86, 96], ["COVID", "TEST", 120, 125], ["IQR", "TEST", 162, 165], ["significant", "OBSERVATION_MODIFIER", 45, 56]]], ["In these patients, 59 (50.8%) were mild pneumonia, and 46 (39.7%) were severe pneumonia, who entered the isolation ward, while 11 (9.5%) were ARDS, who were transferred to intensive care unit (ICU) ( author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Changes of kidney-related clinical indicatorsAs shown in Table 2 and hypoxemia which was difficult to correct.", [["kidney", "ANATOMY", 298, 304], ["pneumonia", "DISEASE", 40, 49], ["pneumonia", "DISEASE", 78, 87], ["ARDS", "DISEASE", 142, 146], ["hypoxemia", "DISEASE", 356, 365], ["patients", "ORGANISM", 9, 17], ["kidney", "ORGAN", 298, 304], ["patients", "SPECIES", 9, 17], ["mild pneumonia", "PROBLEM", 35, 49], ["severe pneumonia", "PROBLEM", 71, 87], ["ARDS", "PROBLEM", 142, 146], ["Changes of kidney-related clinical indicators", "PROBLEM", 287, 332], ["hypoxemia", "PROBLEM", 356, 365], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["pneumonia", "OBSERVATION", 40, 49], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["pneumonia", "OBSERVATION", 78, 87], ["ARDS", "OBSERVATION", 142, 146], ["med", "ANATOMY", 231, 234], ["kidney", "ANATOMY", 298, 304], ["hypoxemia", "OBSERVATION", 356, 365]]], ["Even if invasive ventilation was used, they died from respiratory failure.", [["respiratory", "ANATOMY", 54, 65], ["respiratory failure", "DISEASE", 54, 73], ["invasive ventilation", "TREATMENT", 8, 28], ["respiratory failure", "PROBLEM", 54, 73], ["respiratory failure", "OBSERVATION", 54, 73]]], ["It's worth noting that all of 5 patients with CRF were survived, who did not develop to ARDS or CRF deterioration.", [["CRF", "DISEASE", 46, 49], ["ARDS", "DISEASE", 88, 92], ["CRF", "DISEASE", 96, 99], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["CRF", "PROBLEM", 46, 49], ["ARDS", "PROBLEM", 88, 92], ["CRF deterioration", "PROBLEM", 96, 113], ["ARDS", "OBSERVATION", 88, 92]]], ["Data from above two studies suggested that acute renal impairment was uncommon in COVID-19, and SARS-CoV-2 infection does not significantly cause obvious azotemia and acute renal injury.Changes of kidney-related clinical indicatorsBased on the clinical, pathologic study, and laboratory features of SARS-CoV infection in SARS patients in 2003, the data showed that acute renal impairment was uncommon, but carried a formidably high mortality (91.7%, 33 of 36 cases) [17] .", [["renal", "ANATOMY", 49, 54], ["renal", "ANATOMY", 173, 178], ["kidney", "ANATOMY", 197, 203], ["renal", "ANATOMY", 371, 376], ["acute renal impairment", "DISEASE", 43, 65], ["SARS", "DISEASE", 96, 100], ["infection", "DISEASE", 107, 116], ["azotemia", "DISEASE", 154, 162], ["acute renal injury", "DISEASE", 167, 185], ["SARS-CoV infection", "DISEASE", 299, 317], ["SARS", "DISEASE", 321, 325], ["acute renal impairment", "DISEASE", 365, 387], ["renal", "ORGAN", 49, 54], ["SARS-CoV-2", "ORGANISM", 96, 106], ["renal", "ORGAN", 173, 178], ["kidney", "ORGAN", 197, 203], ["SARS-CoV", "ORGANISM", 299, 307], ["patients", "ORGANISM", 326, 334], ["renal", "ORGAN", 371, 376], ["patients", "SPECIES", 326, 334], ["SARS-CoV-2", "SPECIES", 96, 106], ["SARS-CoV", "SPECIES", 299, 307], ["two studies", "TEST", 16, 27], ["acute renal impairment", "PROBLEM", 43, 65], ["COVID", "TEST", 82, 87], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["2 infection", "PROBLEM", 105, 116], ["obvious azotemia", "PROBLEM", 146, 162], ["acute renal injury", "PROBLEM", 167, 185], ["Changes of kidney-related clinical indicators", "PROBLEM", 186, 231], ["pathologic study", "TEST", 254, 270], ["SARS", "PROBLEM", 299, 303], ["CoV infection", "PROBLEM", 304, 317], ["the data", "TEST", 344, 352], ["acute renal impairment", "PROBLEM", 365, 387], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["renal", "ANATOMY", 49, 54], ["impairment", "OBSERVATION", 55, 65], ["azotemia", "OBSERVATION", 154, 162], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["renal", "ANATOMY", 173, 178], ["injury", "OBSERVATION", 179, 185], ["kidney", "ANATOMY", 197, 203], ["CoV", "OBSERVATION_MODIFIER", 304, 307], ["infection", "OBSERVATION", 308, 317], ["acute", "OBSERVATION_MODIFIER", 365, 370], ["renal", "ANATOMY", 371, 376], ["impairment", "OBSERVATION", 377, 387]]], ["In this study, all of the patients without basic kidney disease showed no obvious abnormality of renal function during the hospitalization of COVID-19, and none of the patients exhibited ARF.", [["kidney", "ANATOMY", 49, 55], ["renal", "ANATOMY", 97, 102], ["kidney disease", "DISEASE", 49, 63], ["abnormality of renal function", "DISEASE", 82, 111], ["ARF", "DISEASE", 187, 190], ["patients", "ORGANISM", 26, 34], ["kidney", "ORGAN", 49, 55], ["renal", "ORGAN", 97, 102], ["patients", "ORGANISM", 168, 176], ["ARF", "GENE_OR_GENE_PRODUCT", 187, 190], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 168, 176], ["this study", "TEST", 3, 13], ["basic kidney disease", "PROBLEM", 43, 63], ["obvious abnormality of renal function", "PROBLEM", 74, 111], ["COVID", "TEST", 142, 147], ["ARF", "PROBLEM", 187, 190], ["kidney", "ANATOMY", 49, 55], ["disease", "OBSERVATION", 56, 63], ["no obvious", "UNCERTAINTY", 71, 81], ["renal", "ANATOMY", 97, 102], ["function", "OBSERVATION", 103, 111], ["ARF", "OBSERVATION", 187, 190]]], ["Be cause high homology of SARS-CoV-2 and SARS-CoV.", [["SARS", "DISEASE", 26, 30], ["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS-CoV", "ORGANISM", 41, 49], ["SARS-CoV", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 41, 49], ["high homology of SARS", "PROBLEM", 9, 30], ["CoV", "TEST", 31, 34], ["SARS", "PROBLEM", 41, 45], ["CoV", "PROBLEM", 46, 49]]], ["The results of this study were similar and consistent with the presentation of renal function injury in SARS.", [["renal", "ANATOMY", 79, 84], ["renal function injury", "DISEASE", 79, 100], ["SARS", "DISEASE", 104, 108], ["renal", "ORGAN", 79, 84], ["this study", "TEST", 15, 25], ["renal function injury in SARS", "PROBLEM", 79, 108], ["consistent with", "UNCERTAINTY", 43, 58], ["renal", "ANATOMY", 79, 84], ["function", "OBSERVATION_MODIFIER", 85, 93], ["injury", "OBSERVATION", 94, 100]]], ["In this study, we also observed that the patients with chronic renal failure (CRF) who were undergone regular continuous renal replacement therapy (CRRT) were infected with SARS-CoV-2, and confirmed as COVID-19.", [["renal", "ANATOMY", 63, 68], ["renal", "ANATOMY", 121, 126], ["chronic renal failure", "DISEASE", 55, 76], ["CRF", "DISEASE", 78, 81], ["SARS", "DISEASE", 173, 177], ["patients", "ORGANISM", 41, 49], ["renal", "ORGAN", 63, 68], ["renal", "ORGAN", 121, 126], ["COVID-19", "DNA", 202, 210], ["patients", "SPECIES", 41, 49], ["SARS-CoV", "SPECIES", 173, 181], ["this study", "TEST", 3, 13], ["chronic renal failure", "PROBLEM", 55, 76], ["CRF)", "PROBLEM", 78, 82], ["regular continuous renal replacement therapy", "TREATMENT", 102, 146], ["CRRT", "TREATMENT", 148, 152], ["CoV", "TEST", 178, 181], ["COVID", "TEST", 202, 207], ["chronic", "OBSERVATION_MODIFIER", 55, 62], ["renal", "ANATOMY", 63, 68], ["failure", "OBSERVATION", 69, 76], ["renal", "ANATOMY", 121, 126], ["replacement", "OBSERVATION", 127, 138]]], ["Except regular CRRT, the monitoring of renal function indicators showed stable, without exacerbation of CRF during the course of treatment of COVID-19.", [["renal", "ANATOMY", 39, 44], ["CRF", "DISEASE", 104, 107], ["COVID-19", "CHEMICAL", 142, 150], ["COVID-19", "CHEMICAL", 142, 150], ["renal", "ORGAN", 39, 44], ["regular CRRT", "TREATMENT", 7, 19], ["the monitoring of renal function indicators", "TEST", 21, 64], ["exacerbation", "PROBLEM", 88, 100], ["CRF", "PROBLEM", 104, 107], ["treatment", "TREATMENT", 129, 138], ["COVID", "TEST", 142, 147], ["renal", "ANATOMY", 39, 44], ["stable", "OBSERVATION_MODIFIER", 72, 78], ["without", "UNCERTAINTY", 80, 87], ["CRF", "OBSERVATION", 104, 107]]], ["The re-examination of CT showed that pulmonary inflammation was gradually absorbed.", [["pulmonary", "ANATOMY", 37, 46], ["pulmonary inflammation", "DISEASE", 37, 59], ["pulmonary", "ORGAN", 37, 46], ["The re-examination of CT", "TEST", 0, 24], ["pulmonary inflammation", "PROBLEM", 37, 59], ["pulmonary", "ANATOMY", 37, 46], ["inflammation", "OBSERVATION", 47, 59]]], ["Unlike a formidably high mortality in SARS complicated with renal impairment, none of the patients died from the aggravation of CRF or from COVID-19 itself caused by infection with SARS-CoV-2.", [["renal", "ANATOMY", 60, 65], ["SARS", "DISEASE", 38, 42], ["renal impairment", "DISEASE", 60, 76], ["CRF", "DISEASE", 128, 131], ["COVID-19", "CHEMICAL", 140, 148], ["infection", "DISEASE", 166, 175], ["SARS", "DISEASE", 181, 185], ["COVID-19", "CHEMICAL", 140, 148], ["renal", "ORGAN", 60, 65], ["patients", "ORGANISM", 90, 98], ["CRF", "GENE_OR_GENE_PRODUCT", 128, 131], ["CoV-2", "ORGANISM", 186, 191], ["patients", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 181, 189], ["a formidably high mortality", "PROBLEM", 7, 34], ["SARS", "PROBLEM", 38, 42], ["renal impairment", "PROBLEM", 60, 76], ["the aggravation of CRF", "PROBLEM", 109, 131], ["COVID", "TEST", 140, 145], ["infection", "PROBLEM", 166, 175], ["SARS", "PROBLEM", 181, 185], ["high", "OBSERVATION_MODIFIER", 20, 24], ["mortality", "OBSERVATION", 25, 34], ["renal", "ANATOMY", 60, 65], ["impairment", "OBSERVATION", 66, 76], ["infection", "OBSERVATION", 166, 175]]], ["It was also suggested that CRRT plays an important role in the treatment of COVID-19 complicated with CRF.Changes of kidney-related clinical indicatorsCRRT is a mode of renal replacement therapy for hemodynamically unstable, fluid overloaded patients and the patients with sepsis and septic shock in management of ARF, especially in the retained in the body.", [["kidney", "ANATOMY", 117, 123], ["renal", "ANATOMY", 169, 174], ["fluid", "ANATOMY", 225, 230], ["body", "ANATOMY", 353, 357], ["COVID", "DISEASE", 76, 81], ["CRF", "DISEASE", 102, 105], ["sepsis", "DISEASE", 273, 279], ["septic shock", "DISEASE", 284, 296], ["ARF", "DISEASE", 314, 317], ["CRF", "GENE_OR_GENE_PRODUCT", 102, 105], ["kidney", "ORGAN", 117, 123], ["renal", "ORGAN", 169, 174], ["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 259, 267], ["ARF", "GENE_OR_GENE_PRODUCT", 314, 317], ["body", "ORGANISM_SUBDIVISION", 353, 357], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 259, 267], ["CRRT", "TREATMENT", 27, 31], ["COVID", "TEST", 76, 81], ["CRF", "PROBLEM", 102, 105], ["renal replacement therapy", "TREATMENT", 169, 194], ["hemodynamically unstable", "PROBLEM", 199, 223], ["fluid overloaded", "PROBLEM", 225, 241], ["sepsis", "PROBLEM", 273, 279], ["septic shock", "PROBLEM", 284, 296], ["management", "TREATMENT", 300, 310], ["ARF", "PROBLEM", 314, 317], ["kidney", "ANATOMY", 117, 123], ["renal", "ANATOMY", 169, 174], ["replacement", "OBSERVATION", 175, 186], ["fluid overloaded", "OBSERVATION", 225, 241], ["sepsis", "OBSERVATION", 273, 279], ["septic shock", "OBSERVATION", 284, 296], ["ARF", "OBSERVATION", 314, 317], ["body", "ANATOMY", 353, 357]]], ["CRRT also can play a role in removing inflammatory mediators and improving immune function in critical patients [20] .", [["patients", "ORGANISM", 103, 111], ["inflammatory mediators", "PROTEIN", 38, 60], ["patients", "SPECIES", 103, 111], ["CRRT", "TREATMENT", 0, 4], ["inflammatory mediators", "TREATMENT", 38, 60]]], ["Nevertheless, the renal function of patients with COVID-19 needs to be monitored regularly, especially in patients with elevated plasma creatinine.", [["renal", "ANATOMY", 18, 23], ["plasma", "ANATOMY", 129, 135], ["COVID-19", "CHEMICAL", 50, 58], ["creatinine", "CHEMICAL", 136, 146], ["COVID-19", "CHEMICAL", 50, 58], ["creatinine", "CHEMICAL", 136, 146], ["renal", "ORGAN", 18, 23], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 106, 114], ["plasma", "ORGANISM_SUBSTANCE", 129, 135], ["creatinine", "SIMPLE_CHEMICAL", 136, 146], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 50, 55], ["elevated plasma creatinine", "PROBLEM", 120, 146], ["renal", "ANATOMY", 18, 23]]], ["In the event of signs of ARF, potential interventions, including CRRT, should be used to protect renal function as early as possible.", [["renal", "ANATOMY", 97, 102], ["ARF", "DISEASE", 25, 28], ["ARF", "GENE_OR_GENE_PRODUCT", 25, 28], ["renal", "ORGAN", 97, 102], ["ARF", "PROBLEM", 25, 28], ["potential interventions", "TREATMENT", 30, 53], ["CRRT", "TREATMENT", 65, 69], ["ARF", "OBSERVATION", 25, 28]]]], "164fed682f989202e3767cb6dc593e6ded33c9b8": [["Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS leading to selective destruction of myelin sheaths and/or oligodendrocytes (Lassmann, 1983) .", [["CNS", "ANATOMY", 65, 68], ["myelin sheaths", "ANATOMY", 105, 119], ["oligodendrocytes", "ANATOMY", 127, 143], ["Multiple sclerosis", "DISEASE", 0, 18], ["MS", "DISEASE", 20, 22], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["myelin sheaths", "CELLULAR_COMPONENT", 105, 119], ["oligodendrocytes", "CELL", 127, 143], ["oligodendrocytes", "CELL_TYPE", 127, 143], ["Multiple sclerosis (MS)", "PROBLEM", 0, 23], ["a chronic inflammatory disease", "PROBLEM", 27, 57], ["the CNS", "PROBLEM", 61, 68], ["selective destruction of myelin sheaths", "PROBLEM", 80, 119], ["sclerosis", "OBSERVATION", 9, 18], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["inflammatory", "OBSERVATION", 37, 49], ["CNS", "ANATOMY", 65, 68], ["selective", "OBSERVATION_MODIFIER", 80, 89], ["destruction", "OBSERVATION", 90, 101], ["myelin sheaths", "OBSERVATION", 105, 119]]], ["The mechanisms behind demyelination or remyelination, however, are poorly understood, although a heterogeneous pathogenesis is suggested owing to detailed investigations of oligodendrocyte pathology in demyelinating lesions (Lucchinetti et al., 1996 .", [["oligodendrocyte", "ANATOMY", 173, 188], ["demyelinating lesions", "ANATOMY", 202, 223], ["demyelination", "DISEASE", 22, 35], ["remyelination", "DISEASE", 39, 52], ["demyelinating lesions", "DISEASE", 202, 223], ["oligodendrocyte", "CELL", 173, 188], ["demyelinating lesions", "CANCER", 202, 223], ["demyelination", "PROBLEM", 22, 35], ["remyelination", "PROBLEM", 39, 52], ["a heterogeneous pathogenesis", "PROBLEM", 95, 123], ["oligodendrocyte pathology", "PROBLEM", 173, 198], ["demyelinating lesions", "PROBLEM", 202, 223], ["demyelination", "OBSERVATION", 22, 35], ["remyelination", "OBSERVATION", 39, 52], ["heterogeneous", "OBSERVATION_MODIFIER", 97, 110], ["pathogenesis", "OBSERVATION", 111, 123], ["demyelinating", "OBSERVATION_MODIFIER", 202, 215], ["lesions", "OBSERVATION", 216, 223]]], ["In particular, it is not yet clear whether oligodendrocytes are primarily affected in the disease or whether they are destroyed together with myelin during active demyelination (Itoyama et al., 1980; Br\u00fcck et al., 1994; Ozawa et al., 1994; Raine, 1994) .", [["oligodendrocytes", "ANATOMY", 43, 59], ["myelin", "ANATOMY", 142, 148], ["demyelination", "DISEASE", 163, 176], ["oligodendrocytes", "CELL", 43, 59], ["myelin", "GENE_OR_GENE_PRODUCT", 142, 148], ["oligodendrocytes", "CELL_TYPE", 43, 59], ["oligodendrocytes", "PROBLEM", 43, 59], ["myelin", "PROBLEM", 142, 148], ["active demyelination", "PROBLEM", 156, 176], ["oligodendrocytes", "OBSERVATION", 43, 59], ["disease", "OBSERVATION", 90, 97], ["active", "OBSERVATION_MODIFIER", 156, 162], ["demyelination", "OBSERVATION", 163, 176]]], ["Oligodendrocyte death is a prominent feature in MS lesions.", [["Oligodendrocyte", "ANATOMY", 0, 15], ["MS lesions", "ANATOMY", 48, 58], ["death", "DISEASE", 16, 21], ["MS", "DISEASE", 48, 50], ["Oligodendrocyte", "CELL", 0, 15], ["MS lesions", "CANCER", 48, 58], ["Oligodendrocyte death", "PROBLEM", 0, 21], ["MS lesions", "PROBLEM", 48, 58], ["prominent", "OBSERVATION_MODIFIER", 27, 36], ["MS", "OBSERVATION_MODIFIER", 48, 50], ["lesions", "OBSERVATION", 51, 58]]], ["It is, however, not yet clear whether oligodendrocytes die via apoptosis or necrosis, which are different mechanisms of cell death (Selmaj et al., 1991; Lucchinetti et al., 1996) .", [["oligodendrocytes", "ANATOMY", 38, 54], ["cell", "ANATOMY", 120, 124], ["necrosis", "DISEASE", 76, 84], ["death", "DISEASE", 125, 130], ["oligodendrocytes", "CELL", 38, 54], ["cell", "CELL", 120, 124], ["oligodendrocytes", "CELL_TYPE", 38, 54], ["apoptosis", "PROBLEM", 63, 72], ["necrosis", "PROBLEM", 76, 84], ["cell death", "PROBLEM", 120, 130], ["apoptosis", "OBSERVATION", 63, 72], ["necrosis", "OBSERVATION", 76, 84], ["cell death", "OBSERVATION", 120, 130]]], ["Dowling et al. (1997) observed that 14 -40% of all degenerating cells in MS lesions are of oligodendroglial lineage and that most of these cells were dying by apoptosis.", [["cells", "ANATOMY", 64, 69], ["MS lesions", "ANATOMY", 73, 83], ["oligodendroglial lineage", "ANATOMY", 91, 115], ["cells", "ANATOMY", 139, 144], ["cells", "CELL", 64, 69], ["MS lesions", "CANCER", 73, 83], ["oligodendroglial lineage", "CELL", 91, 115], ["cells", "CELL", 139, 144], ["degenerating cells", "CELL_TYPE", 51, 69], ["oligodendroglial lineage", "CELL_TYPE", 91, 115], ["all degenerating cells", "PROBLEM", 47, 69], ["MS lesions", "PROBLEM", 73, 83], ["oligodendroglial lineage", "PROBLEM", 91, 115], ["apoptosis", "PROBLEM", 159, 168], ["degenerating cells", "OBSERVATION", 51, 69], ["lesions", "OBSERVATION", 76, 83], ["oligodendroglial lineage", "OBSERVATION", 91, 115], ["apoptosis", "OBSERVATION", 159, 168]]], ["Exposure to heat-treated cerebrospinal fluid from MS patients caused apoptotic death of astrocytes and oligodendrocytes (Menard et al., 1998) .", [["cerebrospinal fluid", "ANATOMY", 25, 44], ["astrocytes", "ANATOMY", 88, 98], ["oligodendrocytes", "ANATOMY", 103, 119], ["MS", "DISEASE", 50, 52], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 25, 44], ["patients", "ORGANISM", 53, 61], ["astrocytes", "CELL", 88, 98], ["oligodendrocytes", "CELL", 103, 119], ["astrocytes", "CELL_TYPE", 88, 98], ["oligodendrocytes", "CELL_TYPE", 103, 119], ["patients", "SPECIES", 53, 61], ["cerebrospinal fluid", "TEST", 25, 44], ["apoptotic death of astrocytes", "PROBLEM", 69, 98], ["oligodendrocytes", "PROBLEM", 103, 119], ["cerebrospinal", "ANATOMY", 25, 38], ["fluid", "OBSERVATION", 39, 44], ["apoptotic death", "OBSERVATION", 69, 84], ["astrocytes", "ANATOMY", 88, 98]]], ["On the other hand, Bonetti and Raine (1997) found that oligodendrocytes express cell death-related molecules such as tumor necrosis factor (TNF) receptors but show no evidence of apoptosis.", [["oligodendrocytes", "ANATOMY", 55, 71], ["cell", "ANATOMY", 80, 84], ["necrosis", "DISEASE", 123, 131], ["oligodendrocytes", "CELL", 55, 71], ["cell", "CELL", 80, 84], ["tumor necrosis factor (TNF) receptors", "GENE_OR_GENE_PRODUCT", 117, 154], ["oligodendrocytes", "CELL_TYPE", 55, 71], ["tumor necrosis factor (TNF) receptors", "PROTEIN", 117, 154], ["cell death", "PROBLEM", 80, 90], ["related molecules", "PROBLEM", 91, 108], ["tumor necrosis factor", "PROBLEM", 117, 138], ["TNF) receptors", "TEST", 140, 154], ["apoptosis", "PROBLEM", 179, 188], ["cell death", "OBSERVATION", 80, 90], ["tumor", "OBSERVATION", 117, 122], ["no evidence of", "UNCERTAINTY", 164, 178], ["apoptosis", "OBSERVATION", 179, 188]]], ["TNF is a key protein in inducing oligodendrocyte death.", [["oligodendrocyte", "ANATOMY", 33, 48], ["oligodendrocyte death", "DISEASE", 33, 54], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["oligodendrocyte", "CELL", 33, 48], ["TNF", "PROTEIN", 0, 3], ["oligodendrocyte death", "PROBLEM", 33, 54], ["oligodendrocyte death", "OBSERVATION", 33, 54]]], ["It mediates apoptosis of oligodendrocytes in vitro (Selmaj and Raine, 1988) , and its overexpression in the CNS leads to demyelination and oligodendrocyte death (Akassoglou et al., 1998) .", [["oligodendrocytes", "ANATOMY", 25, 41], ["CNS", "ANATOMY", 108, 111], ["oligodendrocyte", "ANATOMY", 139, 154], ["demyelination", "DISEASE", 121, 134], ["oligodendrocyte death", "DISEASE", 139, 160], ["oligodendrocytes", "CELL", 25, 41], ["CNS", "ANATOMICAL_SYSTEM", 108, 111], ["oligodendrocyte", "CELL", 139, 154], ["oligodendrocytes", "CELL_TYPE", 25, 41], ["oligodendrocytes", "PROBLEM", 25, 41], ["demyelination", "PROBLEM", 121, 134], ["oligodendrocyte death", "PROBLEM", 139, 160], ["apoptosis", "OBSERVATION_MODIFIER", 12, 21], ["oligodendrocytes", "OBSERVATION", 25, 41], ["CNS", "ANATOMY", 108, 111], ["demyelination", "OBSERVATION", 121, 134]]], ["A recent study revealed a strong association of TNF-\u2423 mRNA expression and active demyelination in MS lesions (Bitsch et al., 2000) .", [["MS lesions", "ANATOMY", 98, 108], ["demyelination", "DISEASE", 81, 94], ["MS", "DISEASE", 98, 100], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 48, 53], ["lesions", "PATHOLOGICAL_FORMATION", 101, 108], ["TNF-\u2423 mRNA", "RNA", 48, 58], ["A recent study", "TEST", 0, 14], ["TNF", "PROBLEM", 48, 51], ["mRNA expression", "PROBLEM", 54, 69], ["active demyelination in MS lesions", "PROBLEM", 74, 108], ["active", "OBSERVATION_MODIFIER", 74, 80], ["demyelination", "OBSERVATION", 81, 94]]]], "55d14f119beceea992f88ace0600486a90c8c4c8": [["ABSTRACT:Dyspnea is an uncomfortable sensation with the potential to cause psychological trauma.", [["Dyspnea", "DISEASE", 9, 16], ["trauma", "DISEASE", 89, 95], ["Dyspnea", "PROBLEM", 9, 16], ["an uncomfortable sensation", "PROBLEM", 20, 46], ["psychological trauma", "PROBLEM", 75, 95], ["Dyspnea", "OBSERVATION", 9, 16]]], ["Patients presenting with acute respiratory failure, particularly when tidal volume is restricted during mechanical ventilation, may experience the most distressing form of dyspnea known as air hunger.", [["respiratory", "ANATOMY", 31, 42], ["acute respiratory failure", "DISEASE", 25, 50], ["dyspnea", "DISEASE", 172, 179], ["air hunger", "DISEASE", 189, 199], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["acute respiratory failure", "PROBLEM", 25, 50], ["tidal volume", "TEST", 70, 82], ["mechanical ventilation", "TREATMENT", 104, 126], ["dyspnea", "PROBLEM", 172, 179], ["air hunger", "PROBLEM", 189, 199], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["respiratory failure", "OBSERVATION", 31, 50], ["mechanical ventilation", "OBSERVATION", 104, 126], ["air hunger", "OBSERVATION", 189, 199]]], ["Air hunger activates brain pathways known to be involved in post-traumatic stress disorder (PTSD), anxiety, and depression.", [["brain", "ANATOMY", 21, 26], ["post-traumatic stress disorder", "DISEASE", 60, 90], ["PTSD", "DISEASE", 92, 96], ["anxiety", "DISEASE", 99, 106], ["depression", "DISEASE", 112, 122], ["brain", "ORGAN", 21, 26], ["Air hunger", "PROBLEM", 0, 10], ["post-traumatic stress disorder", "PROBLEM", 60, 90], ["PTSD", "PROBLEM", 92, 96], ["anxiety", "PROBLEM", 99, 106], ["depression", "PROBLEM", 112, 122], ["post-traumatic stress", "OBSERVATION", 60, 81]]], ["These conditions are considered part of the post-intensive care syndrome.", [["the post-intensive care syndrome", "PROBLEM", 40, 72]]], ["These sequelae may be even more prevalent among patients with acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 68, 79], ["acute respiratory distress syndrome", "DISEASE", 62, 97], ["ARDS", "DISEASE", 99, 103], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["acute respiratory distress syndrome", "PROBLEM", 62, 97], ["ARDS", "PROBLEM", 99, 103], ["sequelae", "OBSERVATION", 6, 14], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory distress syndrome", "OBSERVATION", 68, 97]]], ["Low tidal volume, a mainstay of modern therapy for ARDS is difficult to avoid and is likely to cause air hunger despite sedation.", [["ARDS", "DISEASE", 51, 55], ["Low tidal volume", "PROBLEM", 0, 16], ["modern therapy", "TREATMENT", 32, 46], ["ARDS", "PROBLEM", 51, 55], ["air hunger", "PROBLEM", 101, 111], ["sedation", "TREATMENT", 120, 128], ["tidal volume", "OBSERVATION", 4, 16], ["ARDS", "OBSERVATION", 51, 55], ["air hunger", "OBSERVATION", 101, 111]]], ["Adjunctive neuromuscular blockade does not prevent or relieve air hunger, but it does prevent the patient from communicating discomfort to caregivers.", [["neuromuscular", "ANATOMY", 11, 24], ["neuromuscular blockade", "DISEASE", 11, 33], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["Adjunctive neuromuscular blockade", "TREATMENT", 0, 33], ["air hunger", "PROBLEM", 62, 72], ["communicating discomfort", "PROBLEM", 111, 135], ["air hunger", "OBSERVATION", 62, 72]]], ["Consequently, paralysis may also contribute to the development of PTSD.", [["paralysis", "DISEASE", 14, 23], ["PTSD", "DISEASE", 66, 70], ["paralysis", "PROBLEM", 14, 23], ["PTSD", "PROBLEM", 66, 70], ["paralysis", "OBSERVATION", 14, 23], ["PTSD", "OBSERVATION", 66, 70]]], ["Although research has identified post-ARDS PTSD as a cause for concern and investigators have taken steps to quantify the burden of disease, there is little information to guide mechanical ventilation strategies designed to reduce its occurrence.", [["PTSD", "DISEASE", 43, 47], ["post-ARDS PTSD", "PROBLEM", 33, 47], ["disease", "PROBLEM", 132, 139], ["mechanical ventilation strategies", "TREATMENT", 178, 211], ["disease", "OBSERVATION", 132, 139]]], ["We suggest such efforts will be more successful if they are directed at the known mechanisms of air hunger.", [["air hunger", "DISEASE", 96, 106], ["air hunger", "PROBLEM", 96, 106], ["air hunger", "OBSERVATION", 96, 106]]], ["Investigation of the anti-dyspnea effects of sedative and analgesic drugs commonly used in the ICU and their impact on post-ARDS PTSD symptoms is a logical next step.", [["PTSD", "DISEASE", 129, 133], ["sedative", "TREATMENT", 45, 53], ["analgesic drugs", "TREATMENT", 58, 73], ["post-ARDS PTSD symptoms", "PROBLEM", 119, 142]]], ["While in practice we often accept negative consequences of life-saving therapies as unavoidable, we must understand the negative sequalae of our therapies and work to minimize them under our primary directive to \"first, do no harm\" to our patients.J o u r n a l P r e -p r o o fImagine you have developed acute respiratory distress syndrome (ARDS) and cannot breathe for yourself.", [["acute respiratory distress syndrome", "DISEASE", 305, 340], ["ARDS", "DISEASE", 342, 346], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 239, 247], ["saving therapies", "TREATMENT", 64, 80], ["our therapies", "TREATMENT", 141, 154], ["fImagine", "TREATMENT", 277, 285], ["acute respiratory distress syndrome", "PROBLEM", 305, 340], ["ARDS", "PROBLEM", 342, 346], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["respiratory distress", "OBSERVATION", 311, 331]]], ["A mechanical ventilator supports you, giving small breaths.", [["A mechanical ventilator", "TREATMENT", 0, 23], ["mechanical ventilator", "OBSERVATION", 2, 23]]], ["Hypercapnia resulting from reduced tidal volumes has increased your drive to breathe, and stretch receptors in your lungs are telling you my breaths are too small.", [["lungs", "ANATOMY", 116, 121], ["Hypercapnia", "DISEASE", 0, 11], ["lungs", "ORGAN", 116, 121], ["stretch receptors", "PROTEIN", 90, 107], ["Hypercapnia", "PROBLEM", 0, 11], ["reduced tidal volumes", "PROBLEM", 27, 48], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["tidal volumes", "OBSERVATION", 35, 48], ["lungs", "ANATOMY", 116, 121], ["small", "OBSERVATION_MODIFIER", 157, 162]]], ["The sensation of wanting-needing-to take in more air is a form of dyspnea known as \"air hunger\", a very unpleasant symptom that is singular in its ability to evoke acute anxiety, panic, frustration, and fear 1 .", [["dyspnea", "DISEASE", 66, 73], ["air hunger", "DISEASE", 84, 94], ["anxiety", "DISEASE", 170, 177], ["panic", "DISEASE", 179, 184], ["frustration", "DISEASE", 186, 197], ["dyspnea", "PROBLEM", 66, 73], ["\"air hunger", "PROBLEM", 83, 94], ["a very unpleasant symptom", "PROBLEM", 97, 122], ["acute anxiety", "PROBLEM", 164, 177], ["panic", "PROBLEM", 179, 184], ["acute", "OBSERVATION_MODIFIER", 164, 169], ["anxiety", "OBSERVATION", 170, 177]]], ["You see your care team around your bed and think, do these people know I'm not getting enough air?", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["Because you are sedated and unable to follow what is happening to you, you start to wonder are these people trying to kill me?J o u r n a l P r e -p r o o fOf course, your physicians are doing their best to protect your lungs with smaller breaths, but you may not understand that.", [["lungs", "ANATOMY", 220, 225], ["people", "ORGANISM", 101, 107], ["lungs", "ORGAN", 220, 225], ["people", "SPECIES", 101, 107], ["lungs", "ANATOMY", 220, 225]]], ["To improve the situation, the team gives you more sedation, but you still have trouble breathing comfortably on the ventilator, so they institute neuromuscular blockade to paralyze your breathing muscles.", [["neuromuscular", "ANATOMY", 146, 159], ["muscles", "ANATOMY", 196, 203], ["muscles", "ORGANISM_SUBDIVISION", 196, 203], ["sedation", "TREATMENT", 50, 58], ["trouble breathing", "PROBLEM", 79, 96], ["the ventilator", "TREATMENT", 112, 126], ["neuromuscular blockade", "TREATMENT", 146, 168], ["your breathing muscles", "PROBLEM", 181, 203]]], ["Someone says, \"The patient looks more comfortable now,\" as they walk out of your room.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26]]], ["You now have no way to communicate your discomfort.J o u r n a l P r e -p r o o fSome physicians still believe that contraction of respiratory muscles is the primary cause of dyspnea 2 , although that theory was disproven years ago 3, 4 .", [["respiratory muscles", "ANATOMY", 131, 150], ["respiratory muscles", "DISEASE", 131, 150], ["dyspnea", "DISEASE", 175, 182], ["respiratory muscles", "ORGANISM_SUBDIVISION", 131, 150], ["your discomfort", "PROBLEM", 35, 50], ["contraction of respiratory muscles", "PROBLEM", 116, 150], ["dyspnea", "PROBLEM", 175, 182], ["contraction", "OBSERVATION", 116, 127], ["respiratory muscles", "ANATOMY", 131, 150]]], ["Current evidence shows that air hunger arises from an increase in respiratory drive projecting to the cerebral cortex, and it is normally offset by increased tidal inflation of the lungs.", [["respiratory", "ANATOMY", 66, 77], ["cerebral cortex", "ANATOMY", 102, 117], ["lungs", "ANATOMY", 181, 186], ["air hunger", "DISEASE", 28, 38], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 102, 117], ["lungs", "ORGAN", 181, 186], ["air hunger", "PROBLEM", 28, 38], ["an increase in respiratory drive", "PROBLEM", 51, 83], ["increased tidal inflation of the lungs", "PROBLEM", 148, 186], ["air hunger", "OBSERVATION", 28, 38], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["respiratory drive", "OBSERVATION", 66, 83], ["cerebral cortex", "ANATOMY", 102, 117], ["normally", "OBSERVATION_MODIFIER", 129, 137], ["offset", "OBSERVATION_MODIFIER", 138, 144], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["tidal inflation", "OBSERVATION", 158, 173], ["lungs", "ANATOMY", 181, 186]]], ["Paralysis does not reduce your air hunger because air hunger does not arise from your respiratory muscles 4 .", [["respiratory muscles", "ANATOMY", 86, 105], ["Paralysis", "DISEASE", 0, 9], ["Paralysis", "PROBLEM", 0, 9], ["your air hunger", "PROBLEM", 26, 41], ["air hunger", "PROBLEM", 50, 60], ["respiratory muscles", "ANATOMY", 86, 105]]], ["Your care team may not even be considering the possibility of persistent dyspnea after starting the paralytic 5 .Air hunger is an under-recognized problem in the ICU and beyondAs clinicians, we aim to relieve distress; nonetheless, clinically significant symptoms of posttraumatic stress disorder (PTSD), including nightmares and flashbacks of dyspnea, are estimated to occur in about 22% of general ICU survivors and are considered part of the post-intensive care syndrome (PICS) [12] [13] [14] [15] [16] .", [["dyspnea", "DISEASE", 73, 80], ["posttraumatic stress disorder", "DISEASE", 267, 296], ["PTSD", "DISEASE", 298, 302], ["dyspnea", "DISEASE", 344, 351], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 481, 505], ["persistent dyspnea", "PROBLEM", 62, 80], ["the paralytic", "TREATMENT", 96, 109], ["Air hunger", "PROBLEM", 113, 123], ["distress", "PROBLEM", 209, 217], ["clinically significant symptoms", "PROBLEM", 232, 263], ["posttraumatic stress disorder", "PROBLEM", 267, 296], ["PTSD", "PROBLEM", 298, 302], ["nightmares", "PROBLEM", 315, 325], ["flashbacks", "PROBLEM", 330, 340], ["dyspnea", "PROBLEM", 344, 351], ["general ICU survivors", "TREATMENT", 392, 413], ["the post-intensive care syndrome", "PROBLEM", 441, 473], ["persistent", "OBSERVATION_MODIFIER", 62, 72], ["dyspnea", "OBSERVATION", 73, 80]]], ["These symptoms can coexist with depression, anxiety and other behavioral disorders, and are correlated with recalled respiratory distress during the ICU stay and with duration of mechanical ventilation 10, 17 .", [["respiratory", "ANATOMY", 117, 128], ["depression", "DISEASE", 32, 42], ["anxiety", "DISEASE", 44, 51], ["behavioral disorders", "DISEASE", 62, 82], ["respiratory distress", "DISEASE", 117, 137], ["These symptoms", "PROBLEM", 0, 14], ["depression", "PROBLEM", 32, 42], ["anxiety", "PROBLEM", 44, 51], ["other behavioral disorders", "PROBLEM", 56, 82], ["respiratory distress", "PROBLEM", 117, 137], ["mechanical ventilation", "TREATMENT", 179, 201]]], ["They may be even more common among survivors of ARDS 11, [18] [19] [20] .", [["ARDS", "DISEASE", 48, 52], ["[18] [19] [20]", "SIMPLE_CHEMICAL", 57, 71], ["ARDS", "PROBLEM", 48, 52]]], ["Individual patient factors also contribute to the likelihood of developing PTSD.", [["PTSD", "DISEASE", 75, 79], ["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["PTSD", "PROBLEM", 75, 79], ["PTSD", "OBSERVATION", 75, 79]]], ["Patients with pre-existing common psychiatric diseases appear to be at higher risk of developing post-traumatic stress following critical illness, mechanical ventilation, and ARDS 15, 19 .Air hunger stimulates brain regions involved in development of PTSDThe Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines PTSD as a collection of intrusive distressing symptoms in response to an extreme stressor or traumatic event, characterized by its capacity to provoke fear, helplessness, or horror in response to the threat of injury or death.Air hunger stimulates brain regions involved in development of PTSDSymptoms include frightening thoughts, images, perceptions, and dreams of the stressor or event, which can be associated with re-living of the experience (flashbacks, nightmares), avoidance of reminders of the event, and a negative view of the future 21 .Air hunger stimulates brain regions involved in development of PTSDAir hunger activates the principal cortical regions comprising the \"salience network\" 22 : the anterior insula, anterior cingulate cortex, and amygdala 23,24 -regions of the brain that integrate external stimuli and emotions in a manner necessary to sustain homeostasis and survival 25 .", [["brain", "ANATOMY", 210, 215], ["brain", "ANATOMY", 577, 582], ["brain", "ANATOMY", 899, 904], ["cortical regions", "ANATOMY", 979, 995], ["anterior insula", "ANATOMY", 1039, 1054], ["anterior cingulate cortex", "ANATOMY", 1056, 1081], ["amygdala", "ANATOMY", 1087, 1095], ["brain", "ANATOMY", 1118, 1123], ["psychiatric diseases", "DISEASE", 34, 54], ["post-traumatic stress", "DISEASE", 97, 118], ["critical illness", "DISEASE", 129, 145], ["ARDS", "DISEASE", 175, 179], ["PTSD", "DISEASE", 329, 333], ["helplessness", "DISEASE", 486, 498], ["injury", "DISEASE", 539, 545], ["death", "DISEASE", 549, 554], ["PTSDSymptoms", "DISEASE", 618, 630], ["frightening thoughts", "DISEASE", 639, 659], ["Patients", "ORGANISM", 0, 8], ["brain", "ORGAN", 210, 215], ["brain regions", "MULTI-TISSUE_STRUCTURE", 577, 590], ["brain regions", "MULTI-TISSUE_STRUCTURE", 899, 912], ["PTSDAir", "GENE_OR_GENE_PRODUCT", 940, 947], ["cortical regions", "MULTI-TISSUE_STRUCTURE", 979, 995], ["anterior insula", "MULTI-TISSUE_STRUCTURE", 1039, 1054], ["anterior cingulate cortex", "CANCER", 1056, 1081], ["brain", "ORGAN", 1118, 1123], ["Patients", "SPECIES", 0, 8], ["pre-existing common psychiatric diseases", "PROBLEM", 14, 54], ["post-traumatic stress", "PROBLEM", 97, 118], ["critical illness", "PROBLEM", 129, 145], ["mechanical ventilation", "TREATMENT", 147, 169], ["ARDS", "PROBLEM", 175, 179], ["Air hunger", "PROBLEM", 188, 198], ["Mental Disorders", "PROBLEM", 296, 312], ["PTSD", "PROBLEM", 329, 333], ["intrusive distressing symptoms", "PROBLEM", 353, 383], ["an extreme stressor", "PROBLEM", 399, 418], ["traumatic event", "PROBLEM", 422, 437], ["its capacity", "PROBLEM", 456, 468], ["fear", "PROBLEM", 480, 484], ["helplessness", "PROBLEM", 486, 498], ["horror in response", "PROBLEM", 503, 521], ["injury", "PROBLEM", 539, 545], ["death", "PROBLEM", 549, 554], ["Air hunger", "PROBLEM", 555, 565], ["PTSDSymptoms", "PROBLEM", 618, 630], ["frightening thoughts", "PROBLEM", 639, 659], ["images", "TEST", 661, 667], ["the stressor", "PROBLEM", 696, 708], ["Air hunger stimulates brain regions", "PROBLEM", 877, 912], ["PTSDAir hunger", "PROBLEM", 940, 954], ["post-traumatic stress", "OBSERVATION", 97, 118], ["mechanical ventilation", "OBSERVATION", 147, 169], ["ARDS", "OBSERVATION", 175, 179], ["traumatic", "OBSERVATION", 422, 431], ["injury", "OBSERVATION", 539, 545], ["anterior", "ANATOMY_MODIFIER", 1039, 1047], ["insula", "ANATOMY_MODIFIER", 1048, 1054], ["anterior", "ANATOMY_MODIFIER", 1056, 1064], ["cingulate cortex", "ANATOMY", 1065, 1081], ["amygdala", "ANATOMY_MODIFIER", 1087, 1095], ["brain", "ANATOMY", 1118, 1123], ["external stimuli", "OBSERVATION", 1139, 1155]]], ["The salience network is known to be involved in the development of PTSD 26, 27 .Air hunger stimulates brain regions involved in development of PTSDPost-ICU PTSD symptoms are strongly linked with memories of \"in-ICU frightening experiences\" 10, 13 .", [["brain", "ANATOMY", 102, 107], ["PTSD", "DISEASE", 67, 71], ["PTSD", "DISEASE", 156, 160], ["network", "MULTI-TISSUE_STRUCTURE", 13, 20], ["brain regions", "MULTI-TISSUE_STRUCTURE", 102, 115], ["PTSD", "PROBLEM", 67, 71], ["Air hunger", "PROBLEM", 80, 90], ["PTSD symptoms", "PROBLEM", 156, 169]]], ["Qualitative studies of recalled experiences suggest air hunger plays a central role: In a J o u r n a l P r e -p r o o f study of 30 patients who experienced dyspnea during mechanical ventilation following cardiac surgery, 83% reported having a \"mortal fear of death\" during and after an acute episode of dyspnea 28 .", [["cardiac", "ANATOMY", 206, 213], ["dyspnea", "DISEASE", 158, 165], ["death", "DISEASE", 261, 266], ["dyspnea", "DISEASE", 305, 312], ["patients", "ORGANISM", 133, 141], ["cardiac", "ORGAN", 206, 213], ["patients", "SPECIES", 133, 141], ["Qualitative studies", "TEST", 0, 19], ["air hunger", "PROBLEM", 52, 62], ["dyspnea", "PROBLEM", 158, 165], ["mechanical ventilation", "TREATMENT", 173, 195], ["cardiac surgery", "TREATMENT", 206, 221], ["death", "PROBLEM", 261, 266], ["dyspnea", "PROBLEM", 305, 312], ["air hunger", "OBSERVATION", 52, 62], ["dyspnea", "OBSERVATION", 158, 165], ["mechanical ventilation", "OBSERVATION", 173, 195], ["cardiac", "ANATOMY", 206, 213], ["surgery", "OBSERVATION", 214, 221], ["acute", "OBSERVATION_MODIFIER", 288, 293]]], ["In another study of 126 ICU survivors, 39% recalled feeling at risk of imminent death, and 55% recalled feeling they were being suffocated 29 .Air hunger stimulates brain regions involved in development of PTSDA schema illustrating the hypothesized connections between mechanical ventilation and psychological trauma is shown in the Figure.Dyspnea is associated with PTSD symptomsDyspnea and, inconsistently, duration of mechanical ventilation, have previously been associated with development of PTSD symptoms 6, 10, 13, 17, 28 .", [["brain", "ANATOMY", 165, 170], ["death", "DISEASE", 80, 85], ["trauma", "DISEASE", 310, 316], ["Dyspnea", "DISEASE", 340, 347], ["PTSD symptomsDyspnea", "DISEASE", 367, 387], ["PTSD", "DISEASE", 497, 501], ["brain regions", "MULTI-TISSUE_STRUCTURE", 165, 178], ["imminent death", "PROBLEM", 71, 85], ["Air hunger", "PROBLEM", 143, 153], ["PTSDA schema", "PROBLEM", 206, 218], ["mechanical ventilation", "TREATMENT", 269, 291], ["psychological trauma", "PROBLEM", 296, 316], ["Dyspnea", "PROBLEM", 340, 347], ["PTSD symptomsDyspnea", "PROBLEM", 367, 387], ["mechanical ventilation", "TREATMENT", 421, 443], ["PTSD symptoms", "PROBLEM", 497, 510], ["mechanical ventilation", "OBSERVATION", 269, 291], ["mechanical ventilation", "OBSERVATION", 421, 443]]], ["A study of 80 ARDS survivors showed a correlation between recollection of traumatic experiences including dyspnea or respiratory distress and subsequent PTSD symptoms 11 .", [["respiratory", "ANATOMY", 117, 128], ["ARDS", "DISEASE", 14, 18], ["traumatic experiences", "DISEASE", 74, 95], ["dyspnea", "DISEASE", 106, 113], ["respiratory distress", "DISEASE", 117, 137], ["PTSD", "DISEASE", 153, 157], ["A study", "TEST", 0, 7], ["traumatic experiences", "PROBLEM", 74, 95], ["dyspnea", "PROBLEM", 106, 113], ["respiratory distress", "PROBLEM", 117, 137], ["subsequent PTSD symptoms", "PROBLEM", 142, 166], ["respiratory", "ANATOMY", 117, 128], ["distress", "OBSERVATION", 129, 137]]], ["The conscious and subconscious psychological responses to dyspnea, including memories of frightening ICU experiences, may also contribute to the associated long-term psychiatric sequelae of ICU care that have been described in PICS and are common following ICU stay and ARDS 14, 19, 20, [29] [30] [31] [32] [33] .Dyspnea is associated with PTSD symptomsOne study following 196 survivors of critical illness for a median of about 3 years found that 52% had prolonged psychiatric symptoms: 38% had symptoms of generalized anxiety, 32% had symptoms of depression, and 23% had symptoms of PTSD.", [["dyspnea", "DISEASE", 58, 65], ["psychiatric", "DISEASE", 166, 177], ["PICS", "DISEASE", 227, 231], ["ARDS", "DISEASE", 270, 274], ["Dyspnea", "DISEASE", 313, 320], ["PTSD", "DISEASE", 340, 344], ["critical illness", "DISEASE", 390, 406], ["psychiatric", "DISEASE", 466, 477], ["anxiety", "DISEASE", 520, 527], ["depression", "DISEASE", 549, 559], ["PTSD", "DISEASE", 585, 589], ["PICS", "CANCER", 227, 231], ["[29] [30] [31] [32", "SIMPLE_CHEMICAL", 287, 305], ["dyspnea", "PROBLEM", 58, 65], ["ICU care", "TREATMENT", 190, 198], ["ARDS", "TEST", 270, 274], ["Dyspnea", "PROBLEM", 313, 320], ["PTSD symptoms", "PROBLEM", 340, 353], ["One study", "TEST", 353, 362], ["prolonged psychiatric symptoms", "PROBLEM", 456, 486], ["symptoms", "PROBLEM", 496, 504], ["generalized anxiety", "PROBLEM", 508, 527], ["symptoms", "PROBLEM", 537, 545], ["depression", "PROBLEM", 549, 559], ["symptoms", "PROBLEM", 573, 581], ["PTSD", "PROBLEM", 585, 589]]], ["19 Another study, specifically of ARDS survivors, found that of 102 patients who underwent neuropsychiatric evaluation 1 year following hospitalization, 36% had depression, 62% had anxiety, and 39% had PTSD.", [["ARDS", "DISEASE", 34, 38], ["depression", "DISEASE", 161, 171], ["anxiety", "DISEASE", 181, 188], ["PTSD", "DISEASE", 202, 206], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Another study", "TEST", 3, 16], ["ARDS", "PROBLEM", 34, 38], ["neuropsychiatric evaluation", "TEST", 91, 118], ["depression", "PROBLEM", 161, 171], ["anxiety", "PROBLEM", 181, 188], ["PTSD", "PROBLEM", 202, 206], ["ARDS", "OBSERVATION", 34, 38]]], ["31 \"Low\" tidal volume is relative J o u r n a l P r e -p r o o f A healthy adult at rest may comfortably take tidal volumes of 6-8 mL/kg of ideal body weight (IBW) and will increase tidal volume as part of a normal physiologic response to conditions requiring increased oxygen delivery and minute ventilation, such as exercise or systemic illness.", [["body", "ANATOMY", 146, 150], ["oxygen", "CHEMICAL", 270, 276], ["systemic illness", "DISEASE", 330, 346], ["oxygen", "CHEMICAL", 270, 276], ["body", "ORGANISM_SUBDIVISION", 146, 150], ["tidal", "ORGANISM_SUBDIVISION", 182, 187], ["oxygen", "SIMPLE_CHEMICAL", 270, 276], ["tidal volume", "TEST", 9, 21], ["tidal volumes", "TEST", 110, 123], ["tidal volume", "TREATMENT", 182, 194], ["increased oxygen delivery", "TREATMENT", 260, 285], ["minute ventilation", "TREATMENT", 290, 308], ["systemic illness", "PROBLEM", 330, 346], ["tidal volume", "OBSERVATION", 182, 194]]], ["When lung tissue is injured or inflamed and gas exchange is impaired, as in ARDS, neural input from chemo-, lung, and chest wall receptors can increase respiratory drive and give rise to the sensation of dyspnea 34 , reflexively stimulating further increases in tidal volume 9 .", [["lung tissue", "ANATOMY", 5, 16], ["neural", "ANATOMY", 82, 88], ["lung", "ANATOMY", 108, 112], ["chest wall", "ANATOMY", 118, 128], ["respiratory", "ANATOMY", 152, 163], ["ARDS", "DISEASE", 76, 80], ["dyspnea", "DISEASE", 204, 211], ["lung tissue", "TISSUE", 5, 16], ["lung", "ORGAN", 108, 112], ["inflamed", "PROBLEM", 31, 39], ["ARDS", "PROBLEM", 76, 80], ["chemo-", "TREATMENT", 100, 106], ["chest wall receptors", "TREATMENT", 118, 138], ["increase respiratory drive", "PROBLEM", 143, 169], ["dyspnea", "PROBLEM", 204, 211], ["tidal volume", "TEST", 262, 274], ["lung", "ANATOMY", 5, 9], ["tissue", "OBSERVATION", 10, 16], ["injured", "OBSERVATION", 20, 27], ["inflamed", "OBSERVATION_MODIFIER", 31, 39], ["gas exchange", "OBSERVATION", 44, 56], ["impaired", "OBSERVATION_MODIFIER", 60, 68], ["ARDS", "OBSERVATION", 76, 80], ["lung", "ANATOMY", 108, 112], ["chest", "ANATOMY", 118, 123], ["wall", "ANATOMY_MODIFIER", 124, 128], ["respiratory drive", "OBSERVATION", 152, 169], ["tidal volume", "OBSERVATION", 262, 274]]], ["Patients receiving mechanical ventilation via endotracheal tube will not have control over inspiratory flow rate and airflow will not stimulate \"cool\" receptors in the upper airway; both can contribute to the feeling of inadequate tidal volume 35, 36 .", [["endotracheal tube", "ANATOMY", 46, 63], ["upper airway", "ANATOMY", 168, 180], ["Patients", "ORGANISM", 0, 8], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 46, 63], ["upper airway", "ORGANISM_SUBDIVISION", 168, 180], ["cool\" receptors", "PROTEIN", 145, 160], ["Patients", "SPECIES", 0, 8], ["mechanical ventilation", "TREATMENT", 19, 41], ["endotracheal tube", "TREATMENT", 46, 63], ["inspiratory flow rate", "TEST", 91, 112], ["inadequate tidal volume", "TEST", 220, 243], ["endotracheal tube", "OBSERVATION", 46, 63], ["upper", "ANATOMY_MODIFIER", 168, 173], ["airway", "ANATOMY", 174, 180]]], ["This combination of under-perceived tidal volume and increased drive can provoke air hunger at the tidal volumes typically used in lung protective ventilation, which may be 6 ml/kg IBW or less.Relief from dyspnea can conflict with lung protective ventilationAlthough no studies have examined the relationship of low-tidal volume ventilation strategies to adverse psychiatric outcomes, there are numerous reasons to think a link may exist.", [["lung", "ANATOMY", 131, 135], ["lung", "ANATOMY", 231, 235], ["dyspnea", "DISEASE", 205, 212], ["psychiatric", "DISEASE", 363, 374], ["lung", "ORGAN", 131, 135], ["lung", "ORGAN", 231, 235], ["perceived tidal volume", "TREATMENT", 26, 48], ["increased drive", "PROBLEM", 53, 68], ["air hunger", "PROBLEM", 81, 91], ["the tidal volumes", "TREATMENT", 95, 112], ["lung protective ventilation", "TREATMENT", 131, 158], ["dyspnea", "PROBLEM", 205, 212], ["lung protective ventilation", "TREATMENT", 231, 258], ["studies", "TEST", 270, 277], ["low-tidal volume ventilation strategies", "TREATMENT", 312, 351], ["tidal volume", "OBSERVATION", 36, 48], ["increased drive", "OBSERVATION", 53, 68], ["air hunger", "OBSERVATION", 81, 91], ["tidal volumes", "OBSERVATION", 99, 112], ["lung", "ANATOMY", 131, 135], ["protective ventilation", "OBSERVATION", 136, 158], ["dyspnea", "OBSERVATION", 205, 212], ["lung", "ANATOMY", 231, 235], ["protective ventilation", "OBSERVATION", 236, 258]]], ["Low tidal volume ventilation strategies conflict with the most straightforward form of symptomatic relief from dyspneaa bigger breath 37 .", [["dyspneaa", "DISEASE", 111, 119], ["Low tidal volume ventilation", "TREATMENT", 0, 28], ["symptomatic relief", "PROBLEM", 87, 105], ["dyspneaa bigger breath", "PROBLEM", 111, 133], ["tidal volume", "OBSERVATION", 4, 16]]], ["Patients with ARDS who are receiving low-tidal volume breaths are more likely to experience dyspnea and more likely to be mechanically ventilated for a prolonged period of time, which may put them at increased risk for development of PTSD symptoms 25 .Relief from dyspnea can conflict with lung protective ventilationAcute hypercapnia can also be a powerful provocation for breathing discomfort. in a large international cohort 38 , PCO 2 above 60 mmHg was present at time of ARDS diagnosis in 13.3% of patients.Relief from dyspnea can conflict with lung protective ventilationHealthy patients prevented from taking bigger breaths characterize the experience of hypercapnia as \"like suffocation,\" feeling \"starved for air,\" and \"air hunger\" 7 .", [["lung", "ANATOMY", 290, 294], ["lung", "ANATOMY", 550, 554], ["ARDS", "DISEASE", 14, 18], ["dyspnea", "DISEASE", 92, 99], ["PTSD", "DISEASE", 234, 238], ["dyspnea", "DISEASE", 264, 271], ["hypercapnia", "DISEASE", 323, 334], ["breathing discomfort", "DISEASE", 374, 394], ["ARDS", "DISEASE", 476, 480], ["dyspnea", "DISEASE", 524, 531], ["hypercapnia", "DISEASE", 662, 673], ["suffocation", "DISEASE", 683, 694], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 290, 294], ["patients", "ORGANISM", 503, 511], ["lung", "ORGAN", 550, 554], ["patients", "ORGANISM", 585, 593], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 503, 511], ["patients", "SPECIES", 585, 593], ["ARDS", "PROBLEM", 14, 18], ["low-tidal volume breaths", "TREATMENT", 37, 61], ["dyspnea", "PROBLEM", 92, 99], ["mechanically ventilated", "PROBLEM", 122, 145], ["PTSD symptoms", "PROBLEM", 234, 247], ["dyspnea", "PROBLEM", 264, 271], ["lung protective ventilation", "TREATMENT", 290, 317], ["Acute hypercapnia", "PROBLEM", 317, 334], ["breathing discomfort", "PROBLEM", 374, 394], ["PCO", "TEST", 433, 436], ["ARDS diagnosis", "TEST", 476, 490], ["dyspnea", "PROBLEM", 524, 531], ["lung protective ventilation", "TREATMENT", 550, 577], ["hypercapnia", "PROBLEM", 662, 673], ["suffocation", "PROBLEM", 683, 694], ["ARDS", "OBSERVATION", 14, 18], ["mechanically", "OBSERVATION_MODIFIER", 122, 134], ["ventilated", "OBSERVATION", 135, 145], ["dyspnea", "OBSERVATION", 264, 271], ["lung", "ANATOMY", 290, 294], ["hypercapnia", "OBSERVATION", 323, 334], ["large", "OBSERVATION_MODIFIER", 401, 406], ["ARDS", "OBSERVATION", 476, 480], ["dyspnea", "OBSERVATION", 524, 531], ["lung", "ANATOMY", 550, 554], ["hypercapnia", "OBSERVATION", 662, 673]]], ["Hypercapnia can often be corrected by increasing respiratory rate; nevertheless, permissive hypercapnia to maintain low tidal volumes is still J o u r n a l P r e -p r o o f occasionally necessary 38 .", [["respiratory", "ANATOMY", 49, 60], ["Hypercapnia", "DISEASE", 0, 11], ["hypercapnia", "DISEASE", 92, 103], ["Hypercapnia", "PROBLEM", 0, 11], ["increasing respiratory rate", "PROBLEM", 38, 65], ["permissive hypercapnia", "PROBLEM", 81, 103], ["low tidal volumes", "PROBLEM", 116, 133], ["hypercapnia", "OBSERVATION", 92, 103]]], ["Although patients may eventually adapt to higher PCO 2 39 , adaptation requires several days, making acute rises in PCO 2 especially problematic.Sedatives may not be adequately protectiveMechanically ventilated patients are routinely sedated in hopes of avoiding discomfort, but sedation and amnesia may be incomplete.", [["PCO", "DISEASE", 116, 119], ["amnesia", "DISEASE", 292, 299], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 211, 219], ["acute rises in PCO 2", "PROBLEM", 101, 121], ["Sedatives", "TREATMENT", 145, 154], ["Mechanically ventilated", "TREATMENT", 187, 210], ["sedated", "TREATMENT", 234, 241], ["avoiding discomfort", "PROBLEM", 254, 273], ["sedation", "TREATMENT", 279, 287], ["amnesia", "PROBLEM", 292, 299], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["rises", "OBSERVATION", 107, 112], ["ventilated", "OBSERVATION", 200, 210]]], ["We must also remember that in critically ill patients, excessive sedation may be harmful and increase risk of psychological sequelae.", [["critically ill", "DISEASE", 30, 44], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["excessive sedation", "TREATMENT", 55, 73], ["psychological sequelae", "PROBLEM", 110, 132]]], ["43, 44 In a trial of mechanically ventilated general ICU patients, those receiving no sedation had significantly reduced duration of mechanical ventilation and ICU length of stay 45 .", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["sedation", "TREATMENT", 86, 94], ["mechanical ventilation", "TREATMENT", 133, 155], ["mechanical ventilation", "OBSERVATION", 133, 155]]], ["As patients with ARDS shift from acute illness toward recovery, daily spontaneous awakening and breathing trials-which allow patients to relieve dyspnea symptoms by consciously or subconsciously taking larger tidal volumes-can reduce the duration of mechanical ventilation, symptoms of PTSD, and length of stay 46, 47 .Drugs with anti-dyspneic effects may hold promiseIt is important to make the distinction between sedation, pain relief, dyspnea relief, and relief Propofol, a highly effective amnestic sedative, has been shown to be relatively ineffective at suppressing activation of the amygdala-i.e., patients may still develop maladaptive fear responses to stimuli in the absence of conscious memories 51, 52 .", [["amygdala", "ANATOMY", 591, 599], ["ARDS", "DISEASE", 17, 21], ["acute illness", "DISEASE", 33, 46], ["dyspnea", "DISEASE", 145, 152], ["PTSD", "DISEASE", 286, 290], ["pain", "DISEASE", 426, 430], ["dyspnea", "DISEASE", 439, 446], ["Propofol", "CHEMICAL", 466, 474], ["Propofol", "CHEMICAL", 466, 474], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 125, 133], ["Propofol", "SIMPLE_CHEMICAL", 466, 474], ["amygdala", "ORGAN", 591, 599], ["patients", "ORGANISM", 606, 614], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 606, 614], ["ARDS shift", "PROBLEM", 17, 27], ["acute illness", "PROBLEM", 33, 46], ["daily spontaneous awakening", "TREATMENT", 64, 91], ["breathing trials", "TREATMENT", 96, 112], ["dyspnea symptoms", "PROBLEM", 145, 161], ["larger tidal volumes", "TREATMENT", 202, 222], ["mechanical ventilation", "TREATMENT", 250, 272], ["symptoms", "PROBLEM", 274, 282], ["PTSD", "PROBLEM", 286, 290], ["anti-dyspneic effects", "TREATMENT", 330, 351], ["sedation", "TREATMENT", 416, 424], ["pain relief", "TREATMENT", 426, 437], ["dyspnea relief", "PROBLEM", 439, 453], ["Propofol", "TREATMENT", 466, 474], ["a highly effective amnestic sedative", "TREATMENT", 476, 512], ["maladaptive fear responses", "PROBLEM", 633, 659], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["mechanical ventilation", "OBSERVATION", 250, 272]]], ["Although its effect on dyspnea has not been studied, deep sedation with propofol fails to diminish pain-related activations in the cerebral cortex 53 .", [["cerebral cortex", "ANATOMY", 131, 146], ["dyspnea", "DISEASE", 23, 30], ["propofol", "CHEMICAL", 72, 80], ["pain", "DISEASE", 99, 103], ["propofol", "CHEMICAL", 72, 80], ["propofol", "SIMPLE_CHEMICAL", 72, 80], ["cerebral cortex", "CANCER", 131, 146], ["dyspnea", "PROBLEM", 23, 30], ["deep sedation", "TREATMENT", 53, 66], ["propofol", "TREATMENT", 72, 80], ["diminish pain", "PROBLEM", 90, 103], ["related activations in the cerebral cortex", "PROBLEM", 104, 146], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["cerebral cortex", "ANATOMY", 131, 146]]], ["Further study of our commonly used sedatives and analgesics, many with complex and poorly understood pharmacodynamics, may thus reveal ways to prevent adverse psychological sequelae without sacrificing necessary aspects of critical care.", [["Further study", "TEST", 0, 13], ["sedatives", "TREATMENT", 35, 44], ["analgesics", "TREATMENT", 49, 59], ["adverse psychological sequelae", "PROBLEM", 151, 181], ["critical care", "TREATMENT", 223, 236]]], ["For example, the effects of sedatives like propofol, ketamine, or dexmedetomidine on post-ICU psychiatric disease are largely unknown 54 .Delirium and corticosteroids may mitigate risk of PTSDAlthough delirium has not been independently associated with development of PTSD or other psychiatric outcomes, it commonly complicates critical illness and mechanical ventilation and has been associated with longer ICU stay and prolonged duration of mechanical ventilation 14, 55 .", [["propofol", "CHEMICAL", 43, 51], ["ketamine", "CHEMICAL", 53, 61], ["dexmedetomidine", "CHEMICAL", 66, 81], ["psychiatric disease", "DISEASE", 94, 113], ["Delirium", "DISEASE", 138, 146], ["corticosteroids", "CHEMICAL", 151, 166], ["delirium", "DISEASE", 201, 209], ["PTSD", "DISEASE", 268, 272], ["psychiatric", "DISEASE", 282, 293], ["propofol", "CHEMICAL", 43, 51], ["ketamine", "CHEMICAL", 53, 61], ["dexmedetomidine", "CHEMICAL", 66, 81], ["corticosteroids", "CHEMICAL", 151, 166], ["propofol", "SIMPLE_CHEMICAL", 43, 51], ["ketamine", "SIMPLE_CHEMICAL", 53, 61], ["dexmedetomidine", "SIMPLE_CHEMICAL", 66, 81], ["sedatives", "TREATMENT", 28, 37], ["propofol", "TREATMENT", 43, 51], ["ketamine", "TREATMENT", 53, 61], ["dexmedetomidine", "TREATMENT", 66, 81], ["post-ICU psychiatric disease", "PROBLEM", 85, 113], ["Delirium", "PROBLEM", 138, 146], ["corticosteroids", "TREATMENT", 151, 166], ["PTSDAlthough delirium", "PROBLEM", 188, 209], ["PTSD", "PROBLEM", 268, 272], ["critical illness", "PROBLEM", 328, 344], ["mechanical ventilation", "TREATMENT", 349, 371], ["mechanical ventilation", "TREATMENT", 443, 465], ["mechanical ventilation", "OBSERVATION", 349, 371]]], ["Delirium has been associated with cognitive impairment and functional disability following ICU stay 55 Stimulation of the hypothalamic-pituitary-adrenal axis and the release of cortisol is part of the brain's response to extreme stress 58 .", [["brain", "ANATOMY", 201, 206], ["Delirium", "DISEASE", 0, 8], ["cognitive impairment", "DISEASE", 34, 54], ["functional disability", "DISEASE", 59, 80], ["cortisol", "CHEMICAL", 177, 185], ["cortisol", "CHEMICAL", 177, 185], ["pituitary", "ORGAN", 135, 144], ["adrenal", "ORGAN", 145, 152], ["cortisol", "GENE_OR_GENE_PRODUCT", 177, 185], ["brain", "ORGAN", 201, 206], ["Delirium", "PROBLEM", 0, 8], ["cognitive impairment", "PROBLEM", 34, 54], ["extreme stress", "PROBLEM", 221, 235], ["pituitary", "ANATOMY", 135, 144], ["adrenal axis", "ANATOMY", 145, 157]]], ["Some studies suggest that corticosteroids protect against post-ICU PTSD, while others have found no effect 19, 30, 59 .", [["corticosteroids", "CHEMICAL", 26, 41], ["PTSD", "DISEASE", 67, 71], ["corticosteroids", "CHEMICAL", 26, 41], ["corticosteroids", "SIMPLE_CHEMICAL", 26, 41], ["Some studies", "TEST", 0, 12], ["corticosteroids", "TREATMENT", 26, 41], ["post-ICU PTSD", "PROBLEM", 58, 71]]], ["Administration of corticosteroids in the ICU have been associated with delirium in acute lung injury 60 .", [["lung", "ANATOMY", 89, 93], ["corticosteroids", "CHEMICAL", 18, 33], ["delirium", "DISEASE", 71, 79], ["acute lung injury", "DISEASE", 83, 100], ["corticosteroids", "CHEMICAL", 18, 33], ["lung", "ORGAN", 89, 93], ["corticosteroids", "TREATMENT", 18, 33], ["delirium", "PROBLEM", 71, 79], ["acute lung injury", "PROBLEM", 83, 100], ["corticosteroids", "OBSERVATION", 18, 33], ["associated with", "UNCERTAINTY", 55, 70], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100]]], ["Further research is clearly needed.Research on the psychological effects of neuromuscular blockade in ARDS is limitedNeuromuscular blockade is estimated to be used in 21.7% of all ARDS cases and 37.8% of severe cases worldwide 38 ; little is known about its possible effect on post-ICU psychiatric disease.", [["neuromuscular", "ANATOMY", 76, 89], ["Neuromuscular", "ANATOMY", 117, 130], ["neuromuscular blockade", "DISEASE", 76, 98], ["ARDS", "DISEASE", 102, 106], ["Neuromuscular blockade", "DISEASE", 117, 139], ["ARDS", "DISEASE", 180, 184], ["psychiatric disease", "DISEASE", 286, 305], ["neuromuscular", "ANATOMICAL_SYSTEM", 76, 89], ["Neuromuscular", "MULTI-TISSUE_STRUCTURE", 117, 130], ["neuromuscular blockade", "TREATMENT", 76, 98], ["ARDS", "PROBLEM", 102, 106], ["Neuromuscular blockade", "TREATMENT", 117, 139], ["all ARDS cases", "TEST", 176, 190], ["severe cases worldwide", "PROBLEM", 204, 226], ["post-ICU psychiatric disease", "PROBLEM", 277, 305], ["ARDS", "OBSERVATION", 102, 106]]], ["A confounding factor is that receipt of paralytics may be a marker of disease severity.", [["paralytics", "DISEASE", 40, 50], ["A confounding factor", "PROBLEM", 0, 20], ["paralytics", "TREATMENT", 40, 50], ["disease severity", "PROBLEM", 70, 86], ["disease", "OBSERVATION", 70, 77]]], ["One small observational study of 24 patients showed no association between disease severity and psychiatric outcome, but did show association between psychiatric sequelae and both higher sedative doses and longer duration of neuromuscular blockade 61 .Research on the psychological effects of neuromuscular blockade in ARDS is limitedThe Systemic Early Neuromuscular Blockade (ROSE) study 18 The most important takeaway from the ROSE study supplementary material is that the incidence of significant psychological trauma was high in both groups of mechanically ventilated patients with ARDS.", [["neuromuscular", "ANATOMY", 225, 238], ["neuromuscular", "ANATOMY", 293, 306], ["Neuromuscular", "ANATOMY", 353, 366], ["psychiatric", "DISEASE", 96, 107], ["psychiatric sequelae", "DISEASE", 150, 170], ["neuromuscular blockade", "DISEASE", 293, 315], ["ARDS", "DISEASE", 319, 323], ["trauma", "DISEASE", 514, 520], ["ARDS", "DISEASE", 586, 590], ["patients", "ORGANISM", 36, 44], ["neuromuscular", "ANATOMICAL_SYSTEM", 293, 306], ["patients", "ORGANISM", 572, 580], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 572, 580], ["One small observational study", "TEST", 0, 29], ["disease severity", "PROBLEM", 75, 91], ["psychiatric sequelae", "PROBLEM", 150, 170], ["both higher sedative doses", "TREATMENT", 175, 201], ["neuromuscular blockade", "TREATMENT", 225, 247], ["neuromuscular blockade", "TREATMENT", 293, 315], ["ARDS", "PROBLEM", 319, 323], ["The Systemic Early Neuromuscular Blockade", "TREATMENT", 334, 375], ["the ROSE study", "TEST", 425, 439], ["significant psychological trauma", "PROBLEM", 488, 520], ["ARDS", "PROBLEM", 586, 590], ["small", "OBSERVATION_MODIFIER", 4, 9], ["ARDS", "OBSERVATION", 319, 323], ["significant", "OBSERVATION_MODIFIER", 488, 499], ["psychological", "OBSERVATION_MODIFIER", 500, 513], ["trauma", "OBSERVATION", 514, 520], ["high", "OBSERVATION_MODIFIER", 525, 529], ["mechanically ventilated", "OBSERVATION", 548, 571], ["ARDS", "OBSERVATION", 586, 590]]], ["But it is curious that the prevalence of PTSD symptoms rose in the control group at 12 months.", [["PTSD", "DISEASE", 41, 45], ["PTSD symptoms", "PROBLEM", 41, 54]]], ["One possible explanation is that patients not suffering PTSD were more likely to drop out;Research on the psychological effects of neuromuscular blockade in ARDS is limitedanother possible explanation is that paralyzed patients were more heavily sedated or received more opiates, as evidenced by lower scores on the Richmond Agitation-Sedation (RAS) scale prior to the initiation of paralysis 63 .", [["neuromuscular", "ANATOMY", 131, 144], ["PTSD", "DISEASE", 56, 60], ["neuromuscular blockade", "DISEASE", 131, 153], ["ARDS", "DISEASE", 157, 161], ["paralysis", "DISEASE", 383, 392], ["patients", "ORGANISM", 33, 41], ["neuromuscular", "ANATOMICAL_SYSTEM", 131, 144], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 219, 227], ["PTSD", "PROBLEM", 56, 60], ["neuromuscular blockade", "TREATMENT", 131, 153], ["ARDS", "PROBLEM", 157, 161], ["opiates", "TREATMENT", 271, 278], ["lower scores", "PROBLEM", 296, 308], ["the Richmond Agitation", "TREATMENT", 312, 334], ["Sedation (RAS) scale", "TREATMENT", 335, 355], ["paralysis", "PROBLEM", 383, 392]]], ["It is possible that more drugs with anti-dyspnea effects-namely opiates-were used to achieve deeper sedation in the intervention group.", [["anti-dyspnea", "SIMPLE_CHEMICAL", 36, 48], ["opiates", "SIMPLE_CHEMICAL", 64, 71], ["anti-dyspnea effects", "PROBLEM", 36, 56], ["opiates", "TREATMENT", 64, 71], ["deeper sedation", "TREATMENT", 93, 108], ["the intervention group", "TREATMENT", 112, 134]]], ["Deeper sedation may also have provided more effective amnesia, reducing conscious recollection of events, though trauma may have still been experienced subconsciously.Psychological outcomes must be measured in clinical trialsUntil the ROSE trial, most investigations of ARDS interventions had not examined long-term Large physiologic datasets, such as from ventilators, could be used to determine whether changing ventilator parameters such as inspiratory flow 36 can reduce dyspnea and long term sequelae while remaining within the pressure and volume constraints imposed to minimize lung damage.", [["lung", "ANATOMY", 585, 589], ["amnesia", "DISEASE", 54, 61], ["trauma", "DISEASE", 113, 119], ["ARDS", "DISEASE", 270, 274], ["dyspnea", "DISEASE", 475, 482], ["lung damage", "DISEASE", 585, 596], ["lung", "ORGAN", 585, 589], ["Deeper sedation", "TREATMENT", 0, 15], ["effective amnesia", "PROBLEM", 44, 61], ["trauma", "PROBLEM", 113, 119], ["ARDS interventions", "TREATMENT", 270, 288], ["Large physiologic datasets", "PROBLEM", 316, 342], ["ventilators", "TREATMENT", 357, 368], ["changing ventilator parameters", "TREATMENT", 405, 435], ["inspiratory flow", "TEST", 444, 460], ["dyspnea", "PROBLEM", 475, 482], ["long term sequelae", "PROBLEM", 487, 505], ["the pressure and volume constraints", "TREATMENT", 529, 564], ["lung damage", "PROBLEM", 585, 596], ["long term sequelae", "OBSERVATION_MODIFIER", 487, 505], ["lung", "ANATOMY", 585, 589], ["damage", "OBSERVATION", 590, 596]]], ["Study of the neuro-physiologic basis of ventilator asynchrony and phenomena such as entrainment, characterized as respiratory efforts that are subconsciously matched to rhythms experienced by the body 68 , may also provide new avenues for investigation.", [["respiratory", "ANATOMY", 114, 125], ["body", "ANATOMY", 196, 200], ["ventilator asynchrony", "PROBLEM", 40, 61], ["phenomena", "PROBLEM", 66, 75], ["investigation", "TEST", 239, 252], ["ventilator asynchrony", "OBSERVATION", 40, 61]]], ["For example, music therapy, which introduces an external auditory rhythm, has been associated with reduced anxiety in mechanically ventilated patients.", [["anxiety", "DISEASE", 107, 114], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["music therapy", "TREATMENT", 13, 26], ["an external auditory rhythm", "TREATMENT", 45, 72], ["reduced anxiety in mechanically ventilated patients", "PROBLEM", 99, 150], ["reduced", "OBSERVATION_MODIFIER", 99, 106], ["anxiety", "OBSERVATION", 107, 114], ["mechanically ventilated", "OBSERVATION", 118, 141]]], ["69 We must learn what we can from COVID-19Psychological outcomes must be measured in clinical trialsCOVID-19 will unfortunately lead to tens of thousands around the world requiring mechanical ventilation for ARDS from viral pneumonia, creating massive potential for psychological trauma and mental health sequelae 70 Secondary prevention efforts to address PTSD symptoms in the general post-ICU population, such as trials of counseling 74 and diary programs 75 have, at best, seen limited success.", [["ARDS", "DISEASE", 208, 212], ["viral pneumonia", "DISEASE", 218, 233], ["trauma", "DISEASE", 280, 286], ["PTSD", "DISEASE", 357, 361], ["mechanical ventilation", "TREATMENT", 181, 203], ["ARDS", "PROBLEM", 208, 212], ["viral pneumonia", "PROBLEM", 218, 233], ["psychological trauma", "PROBLEM", 266, 286], ["mental health sequelae", "PROBLEM", 291, 313], ["PTSD symptoms", "PROBLEM", 357, 370], ["viral", "OBSERVATION_MODIFIER", 218, 223], ["pneumonia", "OBSERVATION", 224, 233], ["massive", "OBSERVATION_MODIFIER", 244, 251]]], ["Support of ongoing research in the post-intensive care setting will be critical to our understanding of psychological trauma in the ICU and ways to prevent psychological sequelae from it.SUMMARYMinimizing physical harm and mortality are fundamental goals of critical care interventions, but the risk of psychiatric morbidity in the survivors should not be forgotten.", [["trauma", "DISEASE", 118, 124], ["psychiatric", "DISEASE", 303, 314], ["psychological trauma", "PROBLEM", 104, 124], ["psychological sequelae", "PROBLEM", 156, 178], ["critical care interventions", "TREATMENT", 258, 285], ["psychiatric morbidity", "PROBLEM", 303, 324]]], ["Financial and logistical constraints of clinical trials make studying long-term mental health sequelae of our treatments difficult, J o u r n a l P r e -p r o o f but we believe this must be an important consideration in the design of trials moving forward.", [["clinical trials", "TREATMENT", 40, 55], ["our treatments", "TREATMENT", 106, 120]]], ["Given the particularly high potential for psychological trauma among ARDS survivors following ICU care, we must be thoughtful in recommending low tidal volumes, paralysis, or other uncomfortable therapies in the presence of pre-existing dyspnea and be attentive to the best approaches to mitigate potential complications.", [["trauma", "DISEASE", 56, 62], ["ARDS", "DISEASE", 69, 73], ["paralysis", "DISEASE", 161, 170], ["dyspnea", "DISEASE", 237, 244], ["psychological trauma", "PROBLEM", 42, 62], ["ARDS survivors", "TREATMENT", 69, 83], ["ICU care", "TREATMENT", 94, 102], ["low tidal volumes", "TREATMENT", 142, 159], ["paralysis", "PROBLEM", 161, 170], ["uncomfortable therapies", "TREATMENT", 181, 204], ["pre-existing dyspnea", "PROBLEM", 224, 244], ["potential complications", "PROBLEM", 297, 320], ["dyspnea", "OBSERVATION", 237, 244]]], ["Anti-dyspnea interventions, such as opioids, must be considered along with sedation and analgesia in patients with severe respiratory failure.", [["respiratory", "ANATOMY", 122, 133], ["Anti-dyspnea", "DISEASE", 0, 12], ["respiratory failure", "DISEASE", 122, 141], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["Anti-dyspnea interventions", "TREATMENT", 0, 26], ["opioids", "TREATMENT", 36, 43], ["sedation", "TREATMENT", 75, 83], ["analgesia", "TREATMENT", 88, 97], ["severe respiratory failure", "PROBLEM", 115, 141], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["respiratory failure", "OBSERVATION", 122, 141]]], ["Furthermore, as we recall medicine's first principle to \"do no harm,\" it is essential that studies of the management of these patients include prospective examination of the long-term psychological effects that may be associated with various approaches to sedation, mechanical ventilation, and adjunctive therapies for treatment of severe ARDS.SUMMARYJ o u r n a l P r e -p r o o f", [["ARDS", "DISEASE", 339, 343], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["prospective examination", "TEST", 143, 166], ["sedation", "TREATMENT", 256, 264], ["mechanical ventilation", "TREATMENT", 266, 288], ["adjunctive therapies", "TREATMENT", 294, 314], ["treatment", "TREATMENT", 319, 328], ["severe ARDS", "PROBLEM", 332, 343], ["severe", "OBSERVATION_MODIFIER", 332, 338], ["ARDS", "OBSERVATION", 339, 343]]]], "f1ab74f16ce87b9aba43170749356f9ac8401dd8": [["avoid the risk of virus spread, all potentially exposed subjects are required to be isolated for 14 days, which is the longest predicted incubation time.", [["virus spread", "PROBLEM", 18, 30], ["virus", "OBSERVATION", 18, 23]]], ["However, based on our analysis of a larger dataset available so far, we find there is no observable difference between the incubation time for SARS-CoV-2, severe acute respiratory syndrome coronavirus (SARS-CoV), and middle east respiratory syndrome coronavirus (MERS-CoV), highlighting the need for larger and well-annotated datasets.", [["SARS", "DISEASE", 143, 147], ["acute respiratory syndrome coronavirus", "DISEASE", 162, 200], ["SARS-CoV)", "DISEASE", 202, 211], ["respiratory syndrome coronavirus", "DISEASE", 229, 261], ["SARS-CoV-2", "ORGANISM", 143, 153], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 155, 200], ["SARS-CoV", "ORGANISM", 202, 210], ["middle east respiratory syndrome coronavirus", "ORGANISM", 217, 261], ["MERS-CoV", "ORGANISM", 263, 271], ["SARS-CoV", "SPECIES", 143, 151], ["severe acute respiratory syndrome coronavirus", "SPECIES", 155, 200], ["SARS-CoV", "SPECIES", 202, 210], ["middle east respiratory syndrome coronavirus", "SPECIES", 217, 261], ["MERS-CoV", "SPECIES", 263, 271], ["our analysis", "TEST", 18, 30], ["SARS", "TEST", 143, 147], ["CoV", "TEST", 148, 151], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 155, 200], ["middle east respiratory syndrome coronavirus", "PROBLEM", 217, 261], ["no observable", "UNCERTAINTY", 86, 99], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["respiratory syndrome coronavirus", "OBSERVATION", 168, 200], ["middle", "ANATOMY_MODIFIER", 217, 223], ["respiratory syndrome", "OBSERVATION", 229, 249]]], ["Although phylogenetic analysis indicate it belongs to the same \u03b2-coronavirus genus as severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 has a higher genome-sequence similarity to several \u03b2-coronaviruses detected in bats.", [["acute respiratory syndrome coronavirus", "DISEASE", 93, 131], ["SARS-CoV)", "DISEASE", 133, 142], ["middle east respiratory syndrome coronavirus", "DISEASE", 147, 191], ["\u03b2-coronavirus genus", "ORGANISM", 63, 82], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 86, 131], ["SARS-CoV", "ORGANISM", 133, 141], ["middle east respiratory syndrome coronavirus", "ORGANISM", 147, 191], ["MERS-CoV", "ORGANISM", 193, 201], ["SARS-CoV-2", "ORGANISM", 204, 214], ["\u03b2-coronaviruses", "CANCER", 266, 281], ["\u03b2-coronaviruses", "DNA", 266, 281], ["severe acute respiratory syndrome coronavirus", "SPECIES", 86, 131], ["SARS-CoV", "SPECIES", 133, 141], ["middle east respiratory syndrome coronavirus", "SPECIES", 147, 191], ["MERS-CoV", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 204, 212], ["phylogenetic analysis", "TEST", 9, 30], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 86, 131], ["SARS", "TEST", 133, 137], ["middle east respiratory syndrome coronavirus", "PROBLEM", 147, 191], ["SARS", "PROBLEM", 204, 208], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome coronavirus", "OBSERVATION", 99, 131], ["middle", "ANATOMY_MODIFIER", 147, 153], ["respiratory syndrome", "OBSERVATION", 159, 179]]], ["It shows more than 96% identity to a known bat coronavirus, compared to 79.5% identity to SARS-CoV BJ01.", [["SARS", "DISEASE", 90, 94], ["bat coronavirus", "ORGANISM", 43, 58], ["SARS-CoV BJ01", "ORGANISM", 90, 103], ["bat coronavirus", "SPECIES", 43, 58], ["bat coronavirus", "SPECIES", 43, 58], ["SARS-CoV BJ01", "SPECIES", 90, 103], ["a known bat coronavirus", "PROBLEM", 35, 58], ["SARS", "TEST", 90, 94], ["CoV BJ01", "TEST", 95, 103], ["bat", "ANATOMY", 43, 46], ["coronavirus", "OBSERVATION", 47, 58]]], ["1, 2 Studies investigating the clinical characteristics, epidemic and treatment have also been carried out.", [["2 Studies", "TEST", 3, 12], ["epidemic", "PROBLEM", 57, 65], ["treatment", "TREATMENT", 70, 79]]], ["According to clinical investigation of the pneumonia cases in China, SARS-CoV-2 infection causes SARS with major symptoms such as fever, cough, myalgia, or fatigue and minor symptoms such as sputum production, headache, hemoptysis, and diarrhea.", [["sputum", "ANATOMY", 191, 197], ["pneumonia", "DISEASE", 43, 52], ["SARS", "DISEASE", 69, 73], ["infection", "DISEASE", 80, 89], ["SARS", "DISEASE", 97, 101], ["fever", "DISEASE", 130, 135], ["cough", "DISEASE", 137, 142], ["myalgia", "DISEASE", 144, 151], ["fatigue", "DISEASE", 156, 163], ["headache", "DISEASE", 210, 218], ["hemoptysis", "DISEASE", 220, 230], ["diarrhea", "DISEASE", 236, 244], ["SARS-CoV-2", "ORGANISM", 69, 79], ["CoV-", "SPECIES", 74, 78], ["SARS-CoV-2", "SPECIES", 69, 79], ["the pneumonia cases", "PROBLEM", 39, 58], ["SARS", "PROBLEM", 69, 73], ["2 infection", "PROBLEM", 78, 89], ["SARS", "PROBLEM", 97, 101], ["major symptoms", "PROBLEM", 107, 121], ["fever", "PROBLEM", 130, 135], ["cough", "PROBLEM", 137, 142], ["myalgia", "PROBLEM", 144, 151], ["fatigue", "PROBLEM", 156, 163], ["minor symptoms", "PROBLEM", 168, 182], ["sputum production", "PROBLEM", 191, 208], ["headache", "PROBLEM", 210, 218], ["hemoptysis", "PROBLEM", 220, 230], ["diarrhea", "PROBLEM", 236, 244], ["pneumonia", "OBSERVATION", 43, 52], ["hemoptysis", "OBSERVATION", 220, 230], ["diarrhea", "OBSERVATION", 236, 244]]], ["It is also apparent that the outcome of SARS-CoV-2 pneumonia is enormously destructive, despite a mortality rate less than 3% (according to the latest data on February 8th, 2020 in China 4 ) when compared with SARS-CoV (mortality rate 9.6%) and MERS-CoV (mortality rate 9.6% and 34%).", [["SARS", "DISEASE", 40, 44], ["pneumonia", "DISEASE", 51, 60], ["SARS-CoV", "DISEASE", 210, 218], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "ORGANISM", 210, 218], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 245, 253], ["SARS-CoV", "SPECIES", 40, 48], ["SARS-CoV", "SPECIES", 210, 218], ["MERS-CoV", "SPECIES", 245, 253], ["SARS", "PROBLEM", 40, 44], ["CoV-2 pneumonia", "PROBLEM", 45, 60], ["a mortality rate", "TEST", 96, 112], ["SARS", "TEST", 210, 214], ["mortality rate", "TEST", 220, 234], ["MERS", "TEST", 245, 249], ["CoV", "TEST", 250, 253], ["mortality rate", "TEST", 255, 269], ["pneumonia", "OBSERVATION", 51, 60], ["enormously", "OBSERVATION_MODIFIER", 64, 74], ["destructive", "OBSERVATION_MODIFIER", 75, 86]]], ["5 However, the spread of SARS-CoV-2 infection is much broader than SARS or MERS-CoV and involves larger numbers of patients.", [["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 36, 45], ["SARS", "DISEASE", 67, 71], ["SARS-CoV-2", "ORGANISM", 25, 35], ["MERS-CoV", "ORGANISM", 75, 83], ["patients", "ORGANISM", 115, 123], ["CoV-2", "SPECIES", 30, 35], ["patients", "SPECIES", 115, 123], ["SARS-CoV-2", "SPECIES", 25, 35], ["MERS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 25, 29], ["CoV-2 infection", "PROBLEM", 30, 45], ["spread", "OBSERVATION_MODIFIER", 15, 21], ["infection", "OBSERVATION", 36, 45], ["larger", "OBSERVATION_MODIFIER", 97, 103]]]], "PMC7168567": [["I am writing this from my home, like many of you doing my best to help limit the spread of the Covid-19 virus and \u201cflatten the curve\u201d.", [["Covid-19 virus", "ORGANISM", 95, 109], ["Covid-19 virus", "SPECIES", 95, 109], ["the Covid", "TEST", 91, 100]]], ["In comparison with these challenges, sports and legal issues relating to sports appear quite trivial.", [["trivial", "OBSERVATION", 93, 100]]], ["To the extent that I think about law, I foremost worry that that the corona crisis can be used as an excuse to roll back the rule of law.", [["the corona crisis", "PROBLEM", 65, 82]]], ["History warns us that authoritarians can exploit emergencies and that extreme measures justified by extreme circumstances in the short-term can be hard to remove and used as precedents in the future.", [["extreme measures", "TREATMENT", 70, 86]]]], "PMC6928875": []}